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ABSTRACT
Myogenesis in vertebrates is a complex and intricately regulated process, various
mechanisms of which have been alternately conserved or lost throughout the course of
vertebrate evolution. Mammalian myogenesis is highly regulated by myostatin, a
member of the Transforming Growth Factor-β (TGF-β) family of cytokines, however, a
similar role for myostatin in fish currently remains the subject of inquiry. Myostatin
initiates signal transduction by means of the activin type IIb receptor, and shares
considerable sequence and structural homology across vertebrate taxa, though its
functional homology remains unclear. Two families of transgenic (TG) rainbow trout
(RBT), one in which myostatin was inhibited (PD), and another in which myostatin and
related TGF-β ligands were collectively inhibited (ActRIIB), were utilized to investigate
the growth, morphology, muscle phenotype, and downstream genetic activity proceeding
from myostatin/TGF-β inhibition. Additionally, the well established function of rbST in
rendering increased somatogenesis was investigated in these two families; groups of TG
and non-transgenic (NTG) fish received either a dosage of rbST (50 µg g-1 body weight)
or placebo (sesame oil). Growth and muscularity in TG fish were hypothesized to
surpass that observed in NTG fish in the context of myostatin inhibition. Administration
of rbST resulted in accelerated growth and increased body size in both genotypes in the
ActRIIB and PD families. Growth rate for fish in both families did not differ between
genotypes for fish receiving identical treatments, suggesting that myostatin/TGF-β
inhibition does not augment growth rate in RBT. Neither inhibitory mechanism
increased body size in TG fish beyond that of NTG individuals, demonstrating that these
effectors do not serve a predominant role in constraining absolute growth. While TG
ii

pro-domain fish maintained body size and conformation equivalent to that of NTG fish
within both treatment groups, ActRIIB TG fish remained significantly shorter, with a
significantly lesser body mass and higher condition factor than NTG fish, irrespective of
treatment. The findings presented here suggest that one or more TGF-β molecules,
excluding myostatin, that bind the activin type IIb receptor appear to be involved in axial
patterning and growth potential. A role for a TGF-β molecule other than myostatin in
restricting the capacity for hyperplasia is supported by the increased myofiber density of
the epaxial musculature. Myostatin and related TGF-β molecules were found to impede
expression of the myogenic regulatory factor MyoD, however, increased expression failed
to enhance myogenesis. Myogenin expression was not influenced by the reduction in
myostatin/TGF-β signaling. These data collectively suggest that myostatin and
associated TGF-β molecules are not functioning to restrict muscle growth in basal
teleosts as they are in mammals, although some TGF-β ligands may be involved in
limiting myogenic proliferation. TGF-β molecules other than myostatin do appear to
function to some extent in somite architecture and patterning, and may be necessary to
maintain growth potential. Collectively, these findings support the proposal that
myostatin has evolved differing capacities within the context of disparate vertebrate
physiologies.
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1. INTRODUCTION
The physiology of vertebrate growth is intricately regulated and highly complex,
mediated to varying degrees by genetic, epigenetic, endocrine, and environmental factors
that alternately promote and restrict somatogenesis. Growth in many teleost species,
including salmonids, is unique in that it is indeterminate, persisting throughout ontogeny.
The processes of hypertrophy and hyperplasia that occur in the skeletal muscle produce a
heterogeneous landscape of fibers within the serially repeating myotomes that comprise
the trunk musculature (Johnston et al., 2011; Jobling, 1994; Rescan, 2005). Deciphering
the mechanisms regulating skeletal myogenesis in rainbow trout (Oncorhynchus mykiss)
(RBT) facilitates understanding of a more basal physiology of myogenic regulation and
the evolution of a prominent component of somatogenesis.
The necessity for growth physiologies to operate in a manner that remains
integrated with the host of other physiological processes taking place within an organism
has led to the evolution of a versatile regulation of muscle development. Insulin-like
growth factors-I and –II (IGF-I and IGF-II), somatotropin, insulin, and the somatotropic
axis of which these endocrine effectors are a part, have long been understood to be
integral to myogenesis (Butler and LeRoith, 2001; Johnston et al., 2010). Myostatin, a
member of the transforming growth factor-β (TGF-β) superfamily of endocrine
cytokines, has recently been discovered to be a requisite factor in mammalian
myogenesis (McPherron and Lee, 1997). The protein is a negative regulator of skeletal
muscle, exerting control over cell cycle progression by binding to a transmembrane
receptor complex which transduces an inhibitory signal to intracellular effectors (Liu et
al., 2001; Thomas et al., 2000). However, the extent to which myostatin is involved in
1

myogenic regulation in teleosts, and the conservation of its physiological function across
vertebrate clades, remains to be conclusively elucidated. In an effort to better resolve the
function of myostatin in teleosts, and define potentially conserved functions among
vertebrates, somatic growth was induced in myostatin- and myostatin/TGF-β knockdown
transgenic rainbow trout by means of exogenous somatotropin (rbST). The utilization of
two distinct inhibitory mechanisms, one targeting myostatin as well as related TGF-βs
and the other inhibiting myostatin exclusively, enabled the examination of the role of
myostatin and related cytokines in teleostean myogenesis.
Myostatin has a crucial function in skeletal myogenesis in mammals (McPherron
et al., 1997). It operates as a negative regulator of skeletal muscle, interfering with the
processes of myoblast differentiation and proliferation (Thomas et al., 2000; Taylor et al.,
2001; Langley et al., 2002; Liu et al., 2001). Non-functional myostatin alleles in a
number of domesticated mammalian species have produced a conspicuous phenotype
characterized by excessive skeletal muscle mass, referred to as double-muscling
(McPherron and Lee, 1997; Kambadur et al., 1997; Clop et al., 2006; Mosher et al.,
2007). A similar phenotype has been observed in the skeletal musculature of humans
with myostatin deficiencies (Schuelke et al., 2004). Distinct mutations, one involving a
frameshift subsequent to an oligonucleotide deletion and the other resulting in the loss of
a cysteine residue integral to structural conformation in the Belgian Blue and
Piedmontese cattle breeds, have produced dramatically increased musculature (20-25
percent) resulting from hypertrophic and hyperplastic increases (McPherron and Lee,
1997; Kambadur et al., 1997).
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The conformation of mammalian myostatin is defined by the structural hallmarks
characteristic of proteins of the TGF-β superfamily, including a secretory domain, a
conserved RXXR sequence directing proteolytic cleavage, and a highly conserved
carboxy-terminal domain distinguished by several cysteine residues (McPherron et al.,
1997; McPherron and Lee, 1997). These cysteine residues, and their respective positions,
are essential for the disulfide bonds that form among them to facilitate formation of the
cysteine knot common to TGF-β ligands and requisite for their functionality (McPherron
et al., 1997; McPherron and Lee, 1997). The predicted amino acid sequence of myostatin
demonstrates considerable conservation of the proteolytic cleavage site, as well as the
biologically active domain of the protein. The amino acid sequence of zebrafish (Danio
rerio) shares substantial sequence homology with that of more derived vertebrates,
including murine, avian, and porcine species (Rescan et al., 2001; McPherron and Lee,
1997).
Myostatin is initially translated as a physiologically inactive latent precursor. The
biologically active carboxy-terminal domain remains confined within a complex
comprised of the amino-terminal pro-domain region of the peptide (additionally referred
to as the latency associated protein, LAP) along with other proteins, e.g., the latent TGFβ binding protein (LTBP) (Lee and McPherron, 2001; Munger et al., 1997; Thomas et al.,
2000; de Caestecker, 2004). Following secretion, the latent myostatin complex appears
to remain bound to the extracellular matrix; proteolytic or non-proteolytic cleavage
subsequently liberates myostatin, though the active domain continues to be bound by the
amino-terminal pro-domain, rendering it inactive (Lee and McPherron, 2001; Munger et
al., 1997). Even as a latent precursor, disulfide bonds appear to facilitate formation of
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myostatin homodimers (Lee and McPherron, 2001). The biochemically active, mature
carboxy-terminal myostatin dimer is produced only when proteolytic cleavage by BMP1/metalloproteinase family members separates it from the pro-domain, yielding a
physiologically viable cytokine (Lee, 2004; Lee and McPherron, 2001). It is this
cytokine that binds the extracellular domain of the Activin type IIB serine-threonine
kinase receptor, subsequently recruiting the ALK4 (Activin-like kinase), a type I serinethreonine kinase receptor, thereby forming a heteromeric receptor complex (Lee and
McPherron, 2001; Lee, 2004; Kemaladewi et al., 2012; Derynck and Zhang, 2003).
Myostatin binding initiates a Smad-mediated signaling cascade that ultimately interferes
with myogenic transcription factors such as MyoD and the expression of myogenic genes
(Ge et al., 2011; Massagué, 2000; Liu et al., 2001). Disruption of myogenic gene
expression, along with the up-regulation of cyclin-dependent kinase (CDK) inhibitors
such as p21, which inhibits myoblast proliferation, facilitate the inhibitory role of
myostatin (Thomas et al., 2000; Joulia-Ekaza and Cabello, 2006; Langley et al., 2002;
Taylor et al., 2001).
Recent data have demonstrated that increases in muscle mass in mammals occur
through hypertrophy of the existing tissue and rely minimally upon satellite cell
activation and recruitment (Wang and McPherron, 2012; Amthor et al., 2009). These
findings suggest that myostatin inhibits protein accretion within the skeletal muscle and
myofiber synthesis, rather than inhibiting the proliferation and differentiation of satellite
and precursor cell populations (Amthor et al., 2009; Wang and McPherron, 2012).
However, these investigations have been conducted in murine models that exhibit
determinate growth rather than teleost species possessing indeterminate growth potential.
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Myostatin is subject to regulation by disparate mechanisms at the genome level
and those acting on the signaling cascades or the circulating ligand. The amino-terminal
pro-domain region of the myostatin molecule itself functions as an endogenous
regulatory mechanism as the active carboxy-terminal domain remains latent when bound
to it, only becoming physiologically viable upon cleavage (Lee and McPherron, 2001).
Follistatin binds to, and suppresses, myostatin as well as other TGF-β ligands in a variety
of vertebrate taxa (Haidet et al., 2008; Lee et al., 2010; Medeiros et al., 2009; Rebhan and
Funkenstein, 2008). Myostatin, in the latent and/or active form(s) may be variously
bound in circulation and/or within skeletal muscle by factors including titan-cap, GASP-1
(growth and differentiation factor-associated serum protein-1), FLRG (follistatin-related
gene), and hSGT (human small glutamine-rich tetratricopeptide repeat-containing
protein), all of which operate as myostatin antagonists (Hill et al., 2003; Hill et al., 2002;
Wang et al., 2003; Joulia-Ekaza and Cabello, 2006).
Experimental strategies employed to inhibit myostatin, individually or in
conjunction with other TGF-β ligands, have produced phenotypes paralleling those
observed in animals possessing wild-type loss-of-function myostatin mutations (Lee and
McPherron, 2001). Interfering with TGF-β signaling in an experimental context has
demonstrated that myostatin is but one of an as yet unknown number of regulatory factors
involved in restraining myogenesis, among them Activin A (Lee et al., 2005; Lee et al.,
2010; Lee, 2007). The involvement of additional negative regulators has been
demonstrated by the increased muscling observed in myostatin null mice simultaneously
overexpressing follistatin (Lee, 2007) or a soluble Activin IIB receptor (Lee et al., 2005),
which antagonize multiple TGF-β ligands concomitant with myostatin. Myostatin null
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mice displayed a double-muscle phenotype resembling that observed in cattle breeds with
myostatin deficiencies, as well as significantly increased skeletal muscle mass (Lee,
2007; Lee and McPherron, 2001; McPherron et al. 1997). Hypertrophic and hyperplastic
growth were both found to contribute to the superior musculature of transgenic mice
expressing either follistatin or a dominant negative isoform of the Activin IIB receptor
(Lee and McPherron, 2001). Transgenic expression of follistatin or the pro-domain
region of the endogenous myostatin peptide similarly enhanced muscle hypertrophy (Lee
et al., 2010; Lee, 2007; Yang et al., 2001; Thies et al., 2001).
In teleosts, the function of myostatin, as well as those of many related TGF-β
proteins, remains unresolved, owing perhaps to factors such as diverse growth modes,
genome duplication events, and unique muscle physiologies. Myostatin is nearly
ubiquitously expressed in the tissues of bony fish (Radaelli et al., 2003), the paralogs of
which exhibit tissue-specific differential expression, particularly in the muscle (Roberts
and Goetz, 2001; Østbye et al., 2007; Rescan et al., 2001). Overexpression of the
endogenous myostatin pro-domain in transgenic zebrafish resulted in spatially discrete,
that is, stratified rather than mosaic, hyperplasia of the skeletal muscle; the extent of the
hyperplasia, however, was minimal and hypertrophy was not induced (Xu et al., 2003).
Binding of gilthead seabream (Sparus auratus) myostatin by both follistatin and prodomain constructs has been demonstrated in vitro (Rebhan and Funkenstein, 2008).
Previous work in our lab demonstrated that transgenic rainbow trout (Oncorhynchus
mykiss) overexpressing a follistatin construct exhibited a uniquely muscular phenotype in
the lateral muscle, and hyperplasia of the epaxial and hypaxial skeletal muscle tissue
(Medeiros et al., 2009).
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The functionality of the somatotropic axis, and endocrine factors including IGF-I
and somatotropin (Stitt et al., 2004; Cleveland and Weber, 2009; Seiliez et al., 2010), in
vertebrate myogenesis have been better defined than that of myostatin, and may represent
an opportunity for improved understanding of the role of myostatin in muscle
development. The somatotropic axis and growth physiology have been comprehensively
investigated in teleosts, in particular salmonids, not merely to provide context for the
evolution of somatogenic mechanisms, many of which are homologous in vertebrates,
including rainbow trout (Björnsson et al., 2002; Greene and Chen, 1999; Wood et al.,
2005; LeRoith et al., 2001), but because exploiting these pathways has the potential to
enhance commercial aquaculture (Levesque et al., 2008; de-Santis and Jerry, 2007).
Somatic indices in salmonids have been augmented through both the introduction of
exogenous growth hormone (Garber et al., 1995) and incorporation of growth hormone
transgene constructs (Levesque et al., 2008). Myogenic regulatory factors, as well as
molecular effectors along the somatotropic axis, exhibited similar responses in their
transcriptional profiles to the anabolic effects of exogenous hormone administration and
genetic manipulations (Devlin et al., 2009; Biga et al., 2005; Biga et al., 2004a).
Intensification of somatic growth brought about by transgenesis or exogenous hormone
treatment has been attributed to alterations in metabolic pathways that support increased
myogenesis and efficiency of nutrient utilization (Oakes et al., 2007; Garber et al., 1995);
however, nutritional status profoundly influences the expression of growth-related genes,
indicating differential roles for somatotropic ligands as the nutritional condition of the
fish varies (Montserrat et al., 2007; Amaral and Johnston, 2011; Bower and Johnston,
2010; Erbay et al., 2003; Chauvigné et al., 2003).
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The necessity for rigorous and dynamic regulation of growth imposed by the
demands of integrating somatogenesis and muscle growth with other biological processes
and environmental parameters has resulted in elaborate interactions between the
endocrine effectors involved in this physiology. One such potential interaction may be
that between myostatin and the somatotropin-IGF axis, in which synthesis of the active
myostatin peptide and the expression of myostatin gene copies have been reported to be
moderated by growth hormone (Oldham et al., 2009; Roberts et al., 2004; Biga et al.,
2004b; Liu et al., 2003). Transgenic coho salmon (Oncorhynchus kisutch)
overexpressing growth hormone exhibited decreases in both the production of the mature
peptide and myostatin expression (Roberts et al., 2004). Myostatin-1 and -2 have been
found to possess sequences in their regulatory domains that are subject to influence by
somatotropin (Roberts and Goetz, 2003), suggesting a potential mechanism for
transcriptional control. While the transcriptional and translational repression of
myostatin by growth hormone may suggest that myostatin functions in myogenesis
(Roberts et al., 2004) it may be that the response of myostatin to augmented growth
hormone concentrations is secondary to an increase in anabolic activities. The transgenic
RBT studied here afforded improved understanding of somatotropin action in the context
of myostatin and TGF-β inhibition.
Despite the considerable efforts concentrated on revealing the role of myostatin in
teleosts, a definitive role in myogenesis or other regulatory processes has not been
resolved. Gaining insight into the function of myostatin in RBT has the potential to
reveal the extent of evolutionary conservation or novelty in the myogenic physiology of
vertebrate species. The morphological and ecological exigencies imposed on the
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teleostean and mammalian clades would likely have influenced the evolution of factors
involved in the regulation of an indispensable locomotory tissue such as muscle. To
further elucidate the function of myostatin in salmonids, myogenesis was induced in a
myostatin-knockdown (PD family) and a myostatin/TGF-β-knockdown (ActRIIB family)
line of transgenic RBT through administration of exogenous somatotropin. Myostatin
inhibition was accomplished by the overexpression of the pro-domain region of the
myostatin protein in the PD transgenic fish, which would presumably bind the bioactive
domain and inactivate the peptide. By contrast, myostatin along with related TGF-β
molecules were incapable of accomplishing signal transduction in the ActRIIB family as
the truncated receptor precluded initiation of the intracellular cascade. Stimulation of
growth in the context of myostatin inhibition exclusively, as well as against a background
in which myostatin and related TGF-β ligands had been inhibited, enabled discrimination
of the function of myostatin and other TGF-β cytokines in teleostean myogenesis. It was
anticipated that skeletal muscle growth, the mode of myocyte growth, and expression of
myogenic genes in TG fish would exceed that of NTG fish in the event that myostatin,
alone or in combination with other TGF-β ligands, function to negatively regulate
skeletal muscle development in a basal teleost.
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2. METHODS
2.1 Animals
Transgenic RBT from two distinct families produced at the East Farm
Aquaculture Center in Kingston, RI as previously described (Phelps et al., 2013) were
used for this work. Families were selected from a number of those available due to the
greater percentage of transgenic individuals within them. The members of the two
respective families were F1 full siblings, approximately 7 to 9 months of age at the outset
of the study. The experimental procedures involving these fish were reviewed and
approved by the Institutional Animal Care and Use Committee of the University of
Rhode Island (AN07-04-031 and AN08-02-012).
2.2 Fish husbandry
Fish were fed to satiation 4 to 7 times daily with a commercially available trout
feed (Silver Cup, Tooele, UT, USA) through a combination of manual feeding and an
automated feeding system regulated by a timer (Sweeney, Welfare, TX, USA). Tanks
were supplied with flow through water and supplemental aeration. Water temperature
ranged from 7ºC to 9ºC during the study. Simulated natural photoperiod was maintained
by overhead lighting controlled by automated timers, photoperiod was adjusted as
necessary throughout the study. Prior to each of the five time points at which length and
mass were measured feed was withheld for at least 12 hours to minimize handling stress
and resumed within 24 hours of taking the measurements.
2.3 Constructs and Genetic Screening
One family carried the activin receptor IIB (ActRIIB) transgene construct, which
encodes an isoform of the zebrafish activin IIB receptor in which the encoded protein has
been truncated and the intracellular serine-threonine kinase domain is absent, thereby
10

obstructing signal transduction upon binding of the extracellular domain by myostatin.
Use of the zebrafish activin receptor sequence enabled discrimination of transgenic
individuals from those with the endogenous RBT activin receptor sequence (Phelps et al.,
2013). The other family possessed the pro-domain (PD) transgene construct, in which a
premature stop codon had been inserted into the endogenous myostatin sequence
following the amino-terminal proteolytic cleavage site (Phelps, 2010). ActRIIB and PD
families were screened to distinguish TG and NTG animals for the purposes of
partitioning them into experimental groups. A small piece of tissue was excised from the
caudal fin of each fish while under anesthesia (tricaine methanesulfonate; Western
Chemical, Ferndale, WA, USA; 75 mg L-1) to carry out genomic DNA extraction. Tissue
was placed in 200 µl of lysis buffer (50 mM L-1 KCl, 10mM L-1 Trizma base pH 8.8, 1.5
mM L-1 MgCl2, 0.1% Triton X-100) and heated at 100ºC for 5 minutes in a thermal
cycler (PTC-200, MJ Research, Waltham, MA, USA). Following this, proteinase K (3.2
units, Sigma-Aldrich, St. Louis, MO, USA ) was added and the tissue was digested at
55ºC for one hour, followed by a 10 minute incubation period at 100ºC to denature the
enzyme. Centrifugation of the digested tissue at 6,000 x g for 8 minutes (Allegra 25R,
Beckman Coulter, Brea, CA, USA) provided a supernatant that was used to run constructspecific 25 µl polymerase chain reactions (PCR). The reactions for the screening of the
ActRIIB fish used the following thermal cycler conditions: initial denaturation at 94ºC
for 1 minute, 36 cycles of denaturation at 94ºC for 1 minute, annealing at 63ºC for 30
seconds, and extension at 72ºC for 1 minute, followed by a period of 10 minutes at 72ºC.
The conditions for the screening of the PD group were identical with the exception that
the annealing temperature was 67ºC. The forward and reverse primers for the specific

11

assays are provided in Table 3. All of the reactions made use of Taq DNA polymerase,
Taq Buffer, and deoxynucleotide solution mix (10 mM each nucleotide) (New England
Biolabs, Ipswich, MA, USA) in molecular grade water. The completed reactions were
electrophoresed on a 1% TAE agarose gel containing ethidium bromide in 1X TAE
buffer. The gels were visualized using a Kodak® Gel Logic 100 imaging system
(Carestream Molecular, Rochester, NY, USA).
Passive integrated transponder (PIT) tags (Biomark, Boise, ID, USA) were
implanted in each of the fish to facilitate identification. Additionally, the NTG fish in
both groups had the adipose fin removed to distinguish them from TG individuals. Upon
completion of screening the ActRIIB and PD groups were each transferred to one of two
2 m diameter tanks. The TG and NTG fish from each family were housed communally in
their respective tanks.
2.4 Experimental treatments
Fish were acclimated to the tanks for a minimum of 48 hours prior to
administration of the treatment. Within families, TG and NTG fish were non-selectively
chosen for treatment with either recombinant bovine somatotropin, rbST, (Posilac®, Eli
Lilly, Indianapolis, IN, USA) or sesame oil, which represented the placebo treatment.
The rbST was injected in a single dosage that produced a final concentration of 50 µg g-1
body weight; the volume of Posilac® required to achieve this dosage was calculated based
upon the mass of each fish individually. Sesame oil volumes were determined in the
same manner, using body mass to calculate the volume of oil injected. Treatments were
administered under anesthesia (MS-222) by means of a Microman® positive displacement
pipette (Gilson, Middleton, WI, USA) the tip of which was inserted through a small
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incision made in the ventral body surface which penetrated the coelomic cavity to
promote delivery and sustained release of the respective treatments. Use of the rbST and
placebo treatment generated four groups within each family: rbST-treated transgenic fish
(rbST-treated TG), placebo-treated transgenic fish (placebo TG), rbST-treated nontransgenic fish (rbST-treated NTG), and placebo-treated non-transgenic fish (placebo
NTG). Each of the eight groups contained 20-25 trout.
2.5 Measurement of growth
Injection of the rbST or sesame oil represented the beginning of the experiment
period (day 1), which lasted 84 days. Fork length (mm) and mass (g) of each individual
were measured and recorded on day 1 and then at each 21 day interval. The length and
weight measurements were used to calculate the condition factor (K) for each individual,
according to the formula K = (Wt x 100) ÷ (L3). Specific growth rate for length and mass
was calculated for the interval between each successive time point according to the
formula SGR = ((ln X1 – ln X2) ÷ 21) x 100; where 21 was the number of days between
each time point and X was the length or mass. During measurement fish were
anesthetized to minimize handling stress. Following collection of the growth
measurements the fish were returned to the respective tanks.
2.6 Tissue collection
Following measurement at the final time point (day 84), ten fish from each of the
treatment groups (40 fish per family, 80 fish total) were euthanized with an overdose of
tricaine methane sulfonate and tissue was collected for RNA extraction and histological
sectioning. Using a sterile scalpel, white muscle from the epaxial musculature was
excised and transferred to RNAlater (Ambion, Foster City, CA, USA). The stabilized
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tissue was stored under refrigeration for approximately 24 hours, followed by transfer to
-20ºC until RNA was extracted.
A transverse section 10-15 mm in thickness was cut from each fish immediately
rostral to the leading edge of the dorsal fin. A piece of tissue no more than 4 cm3 was
excised from the epaxial musculature within the section on either side of the dorsoventral midline. The tissue was placed in Tissue-Tek® O.T.C. (Thermo Fisher Scientific,
Pittsburgh, PA, USA) embedding compound within tissue cassettes oriented such that
cross sections could be cut of the longitudinal fibers of the trunk musculature. The tissue
was frozen in 2-methylbutane cooled by liquid nitrogen as previously described
(Medeiros et al., 2009) and stored at -70ºC.
2.7 Muscle morphology
Histological sections 7 µM thick were cut on a Vibratome UltraPro 5000
Advanced cryostat (Bright Instruments, Huntingdon, ENG). Cross sections were cut
from six fish selected from each of the four treatment groups (24 fish per family). The
sections were transferred to Poly-L-Lysine coated slides, and stained using Gill’s
hematoxylin (2%), followed by counterstaining in eosin Y (1%) (Fuentes, 2010).
Sections were preserved with Permount (Thermo Fisher Scientific) and a cover slip, and
visualized and photographed with a Zeiss LSM 5 Pascal microscope (Thornwood, NY,
USA). For each of the six individuals from each treatment group in both families (48 fish
total) three distinct cross sections were prepared and stained on individual slides. To
preclude observer bias tissue samples were sectioned without knowledge of the origin of
the tissue. Images of the histological sections were analyzed using ImagePro Plus
version 5.0.1 (Media Cybernetics, Bethesda, MD, USA). One image was generated from
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each of the three sections cut for each fish. Within each image three 0.2538 mm2 areas of
interest were analyzed (n = 9 per fish). The areas of interest were distinct, neither
touching nor overlapping and free from artifacts and breakages. In performing counts of
the individual fibers any fiber contained in whole or part within the defined area of
interest was regarded as a single fiber and was included in the total number. The fiber
diameter was determined by measuring the shortest distance between the two sides of the
fiber at the approximate midpoint of the fiber. Measurement of the fiber diameters was
carried out only on fibers that were contained entirely within the area of interest. Similar
to sectioning the samples, the fiber number and diameter were measured without
knowledge of the transgenic status or hormone treatment of the individual.
2.8 RNA extraction
Some 50 – 100 mg of each preserved muscle sample were removed from
RNAlater® and transferred to a 2 ml microcentrifuge tube, along with a sterilized 5 mm
stainless steel bead and homogenization buffer (RNeasy Mini Kit®, Qiagen, Valencia,
CA, USA), and homogenized with a Qiagen TissueLyser® at 25 Hz for three 5 minute
intervals. The lysate was centrifuged and the resulting supernatant was applied to silica
columns, and the binding, washing, and elution protocols performed in accordance with
the manufacturer’s instructions; on-column DNase digestion was carried out during the
course of extraction with an RNase-Free DNase kit (Qiagen) to remove contaminating
genomic DNA. The concentration of the total RNA extracted was measured using a
NanoDrop 1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).
Three 2 µl volumes of the RNA eluate were measured and averaged to provide the RNA
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concentration of the sample. The RNA for all samples was diluted to a final
concentration of 25 ng µl-1 for use as template.
2.9 Amplicon cloning and primer design
Assays measuring the expression of the ActRIIB construct, myostatin pro-domain,
and GAPDH had been established previously in the laboratory (Table 3; Phelps, 2010).
The MyoD and myogenin sequences from RBT were cloned to develop RT-qPCR assays
(Tables 2 and 3).

Sequence data for MyoD (GenBank accession number

NM_001124720) and myogenin (GenBank accession number Z46912) were utilized to
design primer pairs (Integrated DNA Technologies: Coralville, IA). The forward primers
were designed such that they contained the palindromic sequence recognized by the
restriction enzyme XbaI (5’-TCTAGA-3’ Table 2). Similarly, the reverse primers were
designed to incorporate the sequence recognized and cut by the restriction enzyme SbfI
(5’-CCTGCAGG-3’).
Total mRNA was used to produce cDNA utilizing oligo dT and Moloney Murine
Leukemia Virus (M-MuLV) reverse transcriptase (New England Biolabs, Ipswich, MA,
USA). This cDNA was used as the template in separate endpoint polymerase chain
reactions using the MyoD or myogenin primer sets, to generate the putative amplicons.
The amplicons were resolved on a 0.8% TAE agarose gel containing ethidium bromide.
The amplicon DNA was purified using the QIAquick PCR purification kit
(Qiagen, Valencia, CA, USA) in accordance with the manufacturer’s instructions, and
quantified as above. 1 µg of the MyoD and myogenin amplicon DNA, as well as 1 µg of
pUC19 vector DNA (New England Biolabs) were digested with XbaI and SbfI (New
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England Biolabs), for two hours at 37ºC. The amplicon and vector DNA were purified
using the QIAquick PCR purification kit.
Ligation of the two amplicons with the vector DNA was performed in separate
reactions using T4 DNA ligase. The ligation reactions were incubated overnight at 16ºC.
Following ligation, chemically competent XL1-blue E. coli cells were transformed with
either the MyoD/pUC19 or myogenin/pUC19 plasmids by means of heat shock per the
manufacturer’s suggestion. Transformed cells were plated on LB agar containing
ampicillin at a concentration of 100 µg ml-1, and incubated at 37ºC overnight.
Isolated colonies were selected from the plates to inoculate Luria Bertani (LB)
broth containing ampicillin (100 µg ml-1), and grown overnight at 37ºC and 250 rpm.
The plasmid DNA was extracted from the cell cultures using a QIAprep Spin Miniprep
kit (Qiagen) in accordance with the manufacturer’s instructions. The plasmid DNA was
sequenced at the Genomics and Sequencing Center at the University of Rhode Island
(URIGSC) using the M13 forward (-20) primer. The presence of the intended clones was
confirmed by referencing the sequences against those available in public databases.
2.10 RT-qPCR
The expression of MyoD and myogenin was determined in the individuals
sampled in the ActRIIB and PD families. Transcription of the ActRIIB transgene
construct was measured in the samples from growth hormone-treated and placebo TG
fish in the ActRIIB; tissue from NTG fish was also assayed to establish absence of the
transcript. The assay utilized to analyze myostatin expression employed primers that
bound the amino-terminal pro-domain region of the transcript, and was therefore unable
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to discriminate between native transcripts and those resulting from the pro-domain
construct.
Expression assays were performed using single-step RT-qPCR with Brilliant II
SYBR Green master mix and reverse transcriptase (Agilent Technologies, Santa Clara,
CA, USA) on a LightCycler 480 (Roche Diagnostics, Indianapolis, IN, USA) at the
URIGSC. Transcriptional activity was measured in ten individuals from each of the four
treatment groups in both the ActRIIB and PD families (40 fish per family) using triplicate
25 µl reactions that contained 50 ng of total RNA template. Expression of the gene of
interest within each sample was normalized to that of GAPDH, which was determined
using a GAPDH-specific assay (Table 3). Potential contamination by genomic DNA was
evaluated in triplicate reactions containing RNA template but lacking reverse
transcriptase; for each treatment group a pooled RNA template was generated from the
ten samples to assess potential contamination in all samples. Triplicate reactions were
carried out without the addition of RNA template to ensure reagents were not
contaminated. Assay-specific standard curves were generated using cDNA amplicons as
the templates for the reactions with copy numbers of the amplicon ranging from 101 to
108.
Expression of the ActRIIB transgene construct was assayed on a LightCycler 480
(Roche Diagnostics) using the following conditions: 50ºC for 30 minutes, 95ºC for 10
minutes, 45 cycles of 95ºC for 30 seconds, and 65ºC for 90 seconds. The myostatin prodomain, MyoD, myogenin, and GAPDH reaction conditions were identical with the
exception of the annealing temperatures, which were 60ºC, 62ºC, 61ºC, and 63ºC,
respectively, and a 60, rather than 90, second extension period. The potential for
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amplification of non-specific sequences was assessed through a dissociation curve
analysis at the conclusion of the amplification phase. Following the final cycle of the
amplification phase the samples were denatured as the temperature was increased from
the respective annealing temperature to 95ºC at a rate of 0.11ºC second-1, while
fluorescence was continuously measured.
2.11 Analysis
Statistical analyses were performed on the length, mass, condition factor, specific
growth rate (length and mass), histological, and gene expression data using SAS, version
9.3 (SAS Institute, Cary, NC, USA). Prior to carrying out the analyses the data were
evaluated for normality using the Shapiro-Wilk test or Kolmogorov-Smirnov test.
Normally distributed data sets were analyzed using a factorial ANOVA that assessed the
impact of both transgenesis and rbST administration, along with any putative interaction
between the two. Subsequently, all of the data were analyzed with four separate one-way
ANOVAs or equivalent nonparametric tests on the basis of genotype and treatment to
validate the results of the factorial ANOVAs and better discriminate differences within
and between both variables. Length, mass, and condition factor data that were not
normally distributed were transformed using the natural log. Data that remained nonnormal following natural log transformation were partitioned by both genotype and
hormone treatment creating four data subsets in which a single variable was evaluated.
These subsets were evaluated with the Mann-Whitney statistic to which, when dictated
by the characteristics of the dataset, the Monte Carlo simulation was added. The
necessity for such an approach was directed by the severity of the departure from
normality within particular data sets. It permitted only direct comparisons between two
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groups on the basis of division by either genotype or hormone treatment, thereby
precluding statistical evaluation of any putative interaction. Any potential interaction
between genotype and hormone treatment could be inferred by comparison of the four
Mann-Whitney tests employed for these particular datasets, though any such interaction
could not be statistically validated. The values provided are mean ± standard error, and
all differences denoted as significant are at the level of p < 0.05 or less.
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3. RESULTS
Fish in both the ActRIIB and PD families tolerated the respective treatments
without incident, and were absent any conspicuous adverse health effects at the
conclusion of the trial period. All fish fed actively throughout the study and displayed no
evidence of infection or disease as evaluated by external examination. Several
individuals were lost over the course of the study due to complications unrelated to the
experimental procedures. The musculature and internal organs of individuals euthanized
to obtain tissue for assays appeared to reflect good health.
3.1 Analyses of morphological parameters and specific growth rate
TG fish in the ActRIIB family were significantly shorter than their NTG siblings
receiving the same treatment, i.e. rbST or placebo, at the beginning of the study;
however, there was no significant difference between the treatment groups within either
the TG or NTG genotypes (Fig. 1). While fish within the same genotype did not differ
significantly in mass between treatments at this time, the placebo TG fish weighed
significantly less (98.11±5.38 g) than did the placebo NTG fish (115.94±5.89 g); no
difference was found between genotypes in the rbST-treated fish (Fig. 2).
At all subsequent time points the TG rbST-treated and placebo ActRIIB fish
remained significantly shorter than NTG fish within the same respective treatment group.
Similarly, the body mass of the TG ActRIIB fish was significantly less than that of the
NTG fish when genotypes were compared within the same treatment group. Begining at
time 2 administration of rbST produced significant differences in the fork length and
mass of treated fish compared to those receiving the placebo. ActRIIB TG fish receiving
rbST were significantly longer (20.08 ±0.41 cm) than placebo TG fish (18.92±0.34 cm),
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while no such difference was found in the lengths of NTG fish (Fig. 1). The rbST-treated
fish of both genotypes were significantly longer than placebo fish of the same respective
genotype at all time points beginning with time 3 (Fig. 1). Exogenous hormone yielded
significantly greater body mass within both genotypes from time 2 throughout the
duration of the study (Fig. 2). Genotype rendered a significant effect on condition factor
for the entirety of the study, as the condition factor of the ActRIIB TG fish receiving
hormone and placebo treatments was significantly higher than the NTG fish within the
same treatment group throughout (Fig. 3). Hormone treatment produced a significantly
higher condition factor within the ActRIIB TG fish at time 4 only, at all other time points
there was no difference between treatment groups in the TG ActRIIB fish. By contrast,
rbST-treated NTG fish possessed a significantly higher condition factor than their
placebo-treated siblings at all time points beginning with the second (Fig. 3). The
interaction between genotype and hormone treatment did not prove significant at any
point.
The SGR evaluated for both the fork length and mass revealed that hormone
treatment yielded a predominant influence on growth (Figs. 7 and 8). With respect to
length, the SGR was significantly greater in the rbST-treated fish, irrespective of
genotype; however, within the ActRIIB TG fish the SGR was not different between
treatments from time point four to five (Fig. 7). The SGR measured for mass was
similarly significant within the rbST-treated fish at all intervals but the last, i.e. between
time points four and five, when no difference was found between treatments in either
genotype. Genetic background, i.e. TG or NTG, failed to generate a differential influence
on the SGR of either length or mass, with a single exception. The SGR of mass in the

22

rbST-treated TG ActRIIB fish was significantly less than that of the rbST-treated NTG
fish between the first and second time points; at all other intervals no difference in
growth rate was found between the TG and NTG fish receiving the same treatment in the
ActRIIB family. The SGR of both length and mass did, however, decrease within the
rbST fish over the course of the experiment, regardless of genotype
The fork length, mass, and condition factor of PD TG fish receiving hormone and
placebo treatments did not differ from those of similarly treated NTG fish at the outset of
the study (Figs. 4-6). At such time no differences were found between treatment groups
within either the TG or NTG fish of the PD family. The length, mass, and condition
factor of the rbST-treated TG and NTG fish emerged as significantly greater than those of
the placebo fish within the same genotype at time point 3; some parameters had achieved
significance as early as time point 2. At no point were any of these metrics significantly
different between the two genotypes for fish in either the rbST or placebo groups;
exogenous somatotropin therefore consistently proved to generate a significant effect
which myostatin inhibition did not. The interaction between genotype and hormone
treatment was not significant for fork length, mass, or condition factor at any point in the
experiment.
The growth rate, measured as a function of both length and mass, was influenced
by rbST throughout the experiment, though not by genetic composition. The SGR for
fish length was significantly greater in the rbST-treated fish of both TG and NTG fish
throughout. Similarly, increases in mass were significantly greater in the rbST-treated
fish of both genotypes; however, a difference in the SGR for mass was observed at
interval 4 in the NTG fish but not in the TG fish. For fish within the same treatment
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group there were no significant differences in the SGR of either length or mass between
TG and NTG fish at any interval between time points. As in the ActRIIB family, the
growth rate of the rbST-treated fish decreased as the experiment proceeded.
3.2 Analyses of histological sections
Myofiber development in epaxial musculature of the ActRIIB fish was impacted
by both the transgene and rbST treatment. The number of myofibers was not
significantly different between the rbST-treated (89.4±1.7) and placebo (88.1±2.1) TG
fish at the time of sampling (Fig. 11). In the NTG fish, however, those treated with rbST
had a significantly greater number of fibers (93±2) than those receiving the placebo
(80.3±1.3); the significant interaction term provided by the factorial ANOVA indicating
that the proliferation of myofibers resulting from rbST treatment was dependent upon the
genetic background, i.e. TG or NTG, into which it was introduced. Moreover, the
number of myofibers in the rbST-treated TG fish (89.4±1.7) was not different from that
of the rbST-treated NTG fish (93±2).
Myofiber diameters in both the TG and NTG fish receiving rbST were
significantly smaller than those of the placebo fish of the same genotype within the
ActRIIB family. Additionally, the fiber diameters of the rbST-treated TG fish
(37.29±0.46 µM) significantly exceeded those of the rbST-treated fish NTG (35.78±0.44
µM) (Fig. 12). However, myofibers in the fish receiving the placebo were significantly
smaller in the TG fish (38.44±0.41 µM) than those of the NTG fish (43.82±0.50 µM).
The inability to carry out a factorial ANOVA analysis on the data due to the non-normal
distribution precluded statistical assessment of any putative interaction between genotype
and treatment. The differential response of the genotypes to the hormone treatment and
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placebo did, however, suggest an interaction between the variables may have been
present; though this could not be statistically validated. Notably, the placebo NTG fish
possessed the largest diameter fibers among the four treatment groups.
Myofiber number in the PD fish was influenced by both genotype and hormone
treatment, as it was in the ActRIIB fish (Fig. 13). A significant interaction existed
between the variables; the administration of rbST differentially influenced muscle cell
proliferation in the two genotypes. Within the TG fish no significant difference in the
number of myofibers was found between the fish treated with rbST (64.1±1.8) and those
receiving the placebo treatment (63.6±2.1) (Fig. 13). NTG fish, however, that were
treated with rbST had a significantly greater number of myofibers (85.4±1.8) than NTG
fish receiving the placebo (61.6±1.2). The number of fibers in the rbST-treated TG fish
was significantly less than that in the NTG fish receiving the hormone treatments; in
contrast no difference was found between genotypes in the fish receiving the placebo.
In both the TG and NTG fish those individuals receiving rbST had significantly
smaller diameter fibers than those receiving the placebo treatment. Additionally, no
significant difference existed between the fiber diameters of the rbST-treated TG fish
(41.60±0.67 µM) and the rbST-treated NTG fish (39.08±0.57 µM) (Fig. 14). The
placebo TG fish did, however, possess significantly smaller diameter fibers (47.70±0.62
µM) than the placebo NTG fish (50.37±0.69 µM). The non-normal distribution of the
data set precluded factorial ANOVA analyses and the evaluation of any interaction
between genotype and hormone treatment.
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3.3 Expression analyses
Expression of the transgene construct in the ActRIIB rbST-treated (0.55±0.09)
and placebo (0.79±0.09) TG fish was not significantly different (Fig. 15). The PCR assay
was designed to detect only the construct, i.e., zebrafish (D. rerio) activin IIB receptor
sequence that codes for a truncated receptor protein; no construct was detected in NTG
fish.
Expression of the myostatin pro-domain in the ActRIIB family did not differ
between genotypes for fish treated with rbST, though it was significantly higher in the
TG fish receiving the placebo (1.34±0.25) when compared to the NTG fish in the same
treatment group (0.52±0.13) (Fig. 16). The assay was specific to the endogenous
myostatin pro-domain and therefore reflected expression of immature form of the peptide.
Myostatin pro-domain expression was not different between the rbST-treated and placebo
fish of either genotype.
Transcription of the muscle regulatory factor MyoD was significantly greater in
the rbST-treated fish than that in plaebo-treated fish of both genotypes. While the
expression was not significantly different between the rbST-treated fish of different
genotypes, MyoD expression in the placebo TG fish (1.26±0.08) was significantly greater
than that of the placebo NTG fish (0.87±0.14) (Fig. 17). The non-normal distribution of
the myogenin expression in the ActRIIB family precluded evaluation of any putative
interaction between genotype and hormone treatment; however, no significant differences
were found in myogenin expression between hormone-treated and placebo fish within
either genotype, or between TG and NTG fish receiving rbST or placebo (Fig. 18).
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In PD fish transcription of the myostatin pro-domain was significantly greater in
both the TG rbST-treated (3.19±0.79) and placebo (1.73±0.18) fish than in the NTG fish
within the same respective treatment group (Fig. 19). Within the two genotypes
expression levels did not differ significantly between treatment types. The assay
measured levels of the endogenous myostatin transcript; therefore transcript levels in the
NTG fish were considered indicative of basal expression and the significantly greater
expression in the TG fish were regarded as a function of the activation of the transgene
construct.
The expression of MyoD in the PD fish was differentially influenced by both
genotype and hormone treatment (Fig. 20). The rbST-treated TG fish (0.98±0.12)
exhibited significantly higher expression than the placebo TG fish, while a difference
between the treatment groups was absent in the NTG fish. TG fish additionally exhibited
significantly higher MyoD transcription than their NTG siblings of the same treatment
type.
Myogenin expression in the PD fish was not significantly different between the
rbST-treated TG (1.12±0.13) and placebo TG (1.39±0.16) fish. Expression in the rbSTtreated NTG fish (1.08±0.08) was significantly lower than that of the placebo NTG fish
(1.76±0.14). No significant differences were found between fish of differing genotypes
receiving the same treatment type (Fig. 21).
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4. DISCUSSION
Myostatin has been established as a potent antagonist of mammalian muscle
growth and development (McPherron and Lee, 1997), functioning to inhibit mitogenic
and terminal maturation programs in myogenic precursors (Thomas et al., 2000; Langley
et al., 2002; Ríos et al., 2002) along with protein synthesis pathways in skeletal muscle
tissue (Taylor et al., 2001). The conservation of myostatin physiology in other vertebrate
taxa remains under investigation, and insight into myostatin function in rainbow trout
facilitates understanding of the evolution of myogenic processes within vertebrates.
Inhibition of myostatin exclusively, as well as alongside related TGF-β molecules,
afforded a unique opportunity to more clearly articulate the function of these endocrine
effectors in teleostean myogenesis. The somatogenesis induced by the administration of
rbST provided a novel context in which to better understand the function and regulation
of myostatin and TGF-β molecules in the muscle growth of a basal teleost. The
transgenic inhibition of these TGF-β proteins indicated that they do not operate to restrict
myogenesis in trout as they do in mammals. While members of the TGF-β family other
than myostatin that signal by means of the activin IIB receptor do appear to influence
axial morphology and myocyte proliferation, none of the peptides examined appear to
function prominently in the myogenesis of RBT.
The TG individuals in the ActRIIB family were defined by a unique phenotype
relative to their NTG siblings, a feature not found in the PD family. The high condition
factor that was the hallmark of the ActRIIB TG fish throughout the duration of the study
resembled that observed by Phelps et al. (2013) in P1 and F1 generations expressing the
same truncated activin receptor construct. Coincident with the greater condition factor in
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the ActRIIB TG fish were a reduced body mass and shorter fork length, that translated to
a more compact morphology. The TG and NTG fish within the ActRIIB family treated
with rbST had a significantly greater fork length and body mass than placebo-treated
siblings of the same respective genotype. Within both treatment groups, however, the TG
fish remained significantly shorter and exhibited a smaller body mass than the NTG
individuals. The morphological differences between the TG and NTG ActRIIB fish
contrasted with the relative uniformity observed in the PD family. The significant
increases in fork length, body mass, and condition factor in the PD family were the result
of administration of rbST; the genetic backgrounds, i.e. TG or NTG, into which the
hormone was introduced failed to generate differences in growth parameters.
The incongruent morphology of TG individuals of the ActRIIB and PD families
corresponded to both the TGF-β ligands being inhibited in the two TG lines, and the
respective mechanism of inhibition. The distinct phenotype observed in the TG ActRIIB
fish in which TGF-βs signaling through the activin IIB receptor were obstructed was not
shared by the TG fish of the PD family, in which myostatin alone was inhibited.
Moreover, in the TG fish of both families a conspicuously muscular appearance
reminiscent of the “double muscled” phenotype characteristic of mammalian species with
myostatin deficiencies, was absent. Several domesticated mammalian species, including
breeds of cattle (McPherron and Lee, 1997; Kambadur et al., 1997; Muroya et al., 2009)
possess nonfunctional myostatin alleles attributable to various mutations. Similar
muscularity in whippets (Mosher et al., 2007) and Texel sheep (Clop et al., 2006) have
additionally revealed decreased myostatin signaling as the causative agent. Transduction
of myostatin signaling to intracellular effectors is dependent upon binding of the
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transmembrane activin receptor complex (Lee and McPherron, 2001; Derynck and
Zhang, 2003). Experimental manipulation of the activin type II receptor yielded mice
with significantly increased skeletal muscle, resembling that found in myostatin-null
models (Lee et al., 2005; Lee and McPherron, 2001). Importantly, muscle mass was
further enhanced in the complete absence of myostatin through the inhibition of related
TGF-β ligands including activin A (Lee et al., 2010), suggesting the participation of
additional effectors alongside myostatin in the regulation of mammalian muscle
physiology (Lee, 2007).
In stark contrast to the exceptionally muscular phenotype produced by
simultaneous inhibition of myostatin and related TGF-β ligands, the TG ActRIIB fish
failed to exhibit a significant increase in myogenesis. Indeed, the TG fish in the ActRIIB
family experienced an alteration in morphology and failed to achieve the body length and
mass attained by NTG siblings. One or more of the endocrine effectors utilizing the
receptor complex of which the activin type IIB hemireceptor is a component appears to
be integral to the myogenic, and even somatogenic, homeostasis that enables typical
growth in these fish.
The specific inhibition of myostatin in the PD family suggests that the
involvement of myostatin in the alteration to morphology and axial development
observed in TG ActRIIB fish is minimal. The PD TG fish diverged only minimally from
the phenotype of their NTG siblings, unlike the significant disparity observed between
genotypes in the ActRIIB family. Notable, however, was the finding that in both families
the TG fish consistently remained smaller in length and body mass than NTG siblings.
While the difference was more pronounced in the ActRIIB TG fish, it is nonetheless of

30

interest that both myostatin-specific and more generalized TGF-β inhibition facilitated a
change in morphology. Comparison of the ActRIIB and PD TG individuals suggests
participation of undetermined TGF-β effectors in both the axial and skeletal muscle
development of basal teleosts. However, the absence of intensified muscle growth in
both families of fish indicates that myostatin and other TGF-β endocrine effectors
investigated here may not function specifically in myogenic physiology, nor are they
likely vigorous antagonists of myogenic growth and regulation in salmonids as they are
in mammals.
Deletion of Gdf11 in mice has been reported to produce alterations to the body
axis and hindlimbs due to homeotic anomolies (McPherron et al., 1999), and though
exploration of any such change was not within the scope of this investigation, gross
anatomy and cursory observation upon dissection of individuals did not indicate similar
modifications. Were such divergent morphology found in trout it may be explained by
the failed signal transduction resulting from GDF11 binding by the truncated activin IIB
receptor. We have previously reported (Phelps et al., 2013) on a striking phenotype
present in members of the P1 generation of ActRIIB trout that was manifestly absent in
the F1 generation. The lateral epaxial and hypaxial musculature of these individuals
exhibited localized muscling present in only some of the somites along the body axis; this
phenotype additionally served to support the expression and functionality of the
transgene construct. The ActRIIB TG fish utilized in the current work were from the F1
generation, and did not possess the localized enhanced musculature that was predominant
in the P1 generation. The offspring of the individuals originally injected with the
ActRIIB transgene construct have therefore been demonstrated to experience differential
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body morphology with a concomitant loss of the regionalized musculature present in their
progenitors. The effects of transgenesis on the F1 generation evidence a consistent role
for TGF-β peptides in the growth and development of the skeletal muscle, as well as
other tissues. While the unique phenotype observed in the P1 generation may be attributed
to epigenetic expression subsequent to injection with high concentrations of the construct,
or differential expression owing to unknown factors, the establishment of the truncated
receptor in the subsequent generation produces a singular, albeit alternative, phenotype.
The P1 generation was also defined by unique phenotypes in each of the TG individuals,
which contrasted with the relatively uniform phenotype observed in all of the F1 ActRIIB
TG fish in this study.
Specific growth rate was not influenced to any discernible degree by the
inhibition of myostatin, either alone or in concert with other TGF-βs, further supporting a
limited role for myostatin in muscle growth, at least for the duration of the life cycle
examined here. The fish in both families had not reached sexual maturity, and were
studied at a stage of life in which they would have been expected to experience
accelerated growth. The ability of the ActRIIB TG fish to sustain equivalent growth rates
with their NTG siblings, despite being consigned to suboptimal body size early in
ontogeny, suggests that TGF-β inhibition constrains growth, but that somatogenesis is
sufficiently plastic to enable growth rates proportional to their reduced size when
permissible conditions allow, i.e. the introduction of exogenous hormone. Further, the
morphological differences observed between these fish are established early in ontogeny
by the deficiency in TGF-β signaling, and persist despite augmentation through extrinsic
growth hormone. The somatotropic axis remains among the foremost mediators of

32

vertebrate growth (Björnsson, 1997) and has remained remarkably well conserved
throughout vertebrate evolution with respect to many of its principal endocrine effectors,
tissues, and receptors (LeRoith et al., 2001). Somatic growth in the rbST-treated
individuals in both families studied here supports the ubiquity of this vertebrate
physiology and the definitive role it has in fish growth.
Considerable effort has been invested in illuminating and exploiting the
somatotropic axis in a number of commercially valuable fish species in an attempt to
encourage greater growth potential (De-Santis and Jerry, 2007). Exogenous recombinant
hormone has been demonstrated to promote growth in salmonids (Agellon et al., 1988;
Garber et al., 1995; Schulte et al., 1989; McLean et al., 1997) as well as other species
(Peterson et al., 2004; Wille et al., 2002). Growth hormone transgenesis has also
succeeded in stimulating significant growth in salmonids (Devlin et al., 1995; Raven et
al., 2012). The increase in growth rate is associated with concomitant modifications to
the expression profiles of a suite of genes concerned with metabolic and growth
physiologies (Raven et al., 2008; Overturf et al., 2010; Raven et al., 2012), relying on a
redistribution and alternative utilization of metabolites to provision the anabolic
processes of growth (Leggatt et al., 2009). Both the specific growth rate and the
increased size of the fish that received rbST in the ActRIIB and PD families support
previous findings. However, the failure of TG individuals to achieve a skeletal muscle
phenotype and growth surpassing that of NTG fish demonstrates the absence of a highly
muscle-specific or substantial role for either myostatin or select TGF-β proteins inhibited
here in the myogenesis of these fish. Were these ligands prominently involved in muscle
development, the placebo TG individuals would presumably have exhibited growth
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beyond that found in their NTG siblings. Additionally, TG fish receiving hormone
treatments might be expected to exceed their NTG sibling in some form of an additive
effect, however, neither event occurred. Instead, the specific growth rates of TG and
NTG fish in both families were equivalent within the respective treatment groups
throughout the duration of the study.
Characteristic of both families was an accelerated growth rate induced by the
anabolic effects of rbST administration, regardless of myostatin or TGF-β inhibition.
The convergent effects of growth hormone transgenesis and selective breeding focused
on enhancing growth performance have revealed that essentially identical pathways and
regulatory programs are responsive to these two disparate mechanisms of somatogenic
augmentation (Devlin et al., 2009; Overturf et al., 2010; Raven et al., 2012). In such
studies the domesticated breeds in which maximal growth potential had been encouraged
typically grew at rates, and in a manner similar, to TG fish (Devlin et al., 2001);
moreover, additional growth was not realized in growth hormone TG fish receiving
exogenous hormone treatment (Raven et al., 2012). The authors suggested that the
capacity for somatogenesis had been nearly exhausted by either artificial selection or
transgenesis in nearly equivalent terms. In the current study, the ability of rbST to
similarly stimulate growth in the TG and NTG fish, coupled with the fact that TG fish
receiving a placebo treatment neither surpassed NTG fish nor approached the growth of
hormone treated fish suggests that myostatin and TGF-β inhibition do not translate to the
bolstered growth potential observed in growth hormone TG fish. Regarded collectively,
the fish used in this study should not be considered to have achieved the maximal growth
permissible by genetic selection as they were bred from stocks not previously selected for
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accelerated growth or commercial production. Additional support for the critical function
of TGF-βs in somatic development and patterning is provided by the more uniformly
compact body shape in the ActRIIB TG fish that is lacking in the PD TG fish and the
difference in the condition factor between TG and NTG fish within the ActRIIB family.
Growth hormone TG salmon exhibit somatogenesis in a homogeneous fashion
throughout the body, without growth concentrated in a particular tissue or region of the
body (Devlin et al., 2004); the compressed morphometrics of the ActRIIB TG fish here
were similarly uniform. As in the growth hormone TG fish, the ActRIIB TG fish
exhibited alterations throughout the body that were likely established early in ontogeny as
a function of constitutive endogenous expression of the truncated receptor, and
maintained as the fish aged. Within the rbST-treated group the increased condition factor
of the TG fish relative to the NTG fish that persisted throughout the study demonstrated
that the compact body form was maintained even as the TG fish grew at a rate equivalent
to that of the NTG fish. The preservation of this morphology suggests endocrine and
paracrine or autocrine functions of the TGF-βs being inhibited by the nonfunctional
receptor as the unique body form is proportional and absent any localized anatomical
anomalies.
The myocyte composition of the epaxial musculature was not markedly altered by
the inhibition of myostatin or TGF-β effectors in either the ActRIIB or PD families. The
fibers examined were derived from the glycolytic somatic musculature within the body
mass and were representative of the epaxial phenotype. However, increased hyperplastic
growth in the TG fish of the ActRIIB family contrasted sharply with the distinct paucity
of hyperplasia to an equivalent degree in the TG fish of the PD family. As the inhibition
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of myostatin exclusively in the PD family failed to generate a phenotype marked by the
more extensive hyperplasia seen in the TG ActRIIB fish, it would appear that TGF-β
molecules other than myostatin signaling by means of the activin IIB receptor are
necessary to impede cell proliferation. Hyperplastic growth has previously been
demonstrated in our lab in RBT expressing the ActRIIB transgene construct (Phelps et
al., 2013) as well as those overexpressing the myostatin/TGF-β antagonist follistatin
(Medeiros et al. 2009). While increased hyperplasia has been reported in zebrafish over
expressing the PD (Xu et al., 2003) this species has a determinate growth mode that
differs from the indeterminate growth found in salmonids.
The degree of hyperplasia observed in the ActRIIB fish was, notably, not
intensified by the administration of rbST. Proliferation in the NTG rbST-treated fish of
the ActRIIB family did not differ from that of the TG fish in the rbST-treated group. It
may be that the proliferative capacity of the TG fish had been fully exploited by
inhibition of a TGF-β effector regulating myoblast proliferation in these fish. Exogenous
hormone administration, in the event of the tissue having fully attained its mitotic
capability and thereby depleting its proliferative ability, would fail to generate
hyperplasia beyond that which had already occurred. If the myoblasts had exhausted
their mitotic potential through the unrestrained proliferation permitted by TGF-β
deregulation they would presumably move towards terminal differentiation. This does
not, however, account for the inability of rbST to elicit an increase in hyperplasia in the
TG fish of the PD family. The absence of a difference in myofiber number in placebotreated TG and NTG PD fish suggests that myostatin is not the primary mediator of
cellular proliferation. However, overexpression of the pro-domain of the endogenous

36

myostatin protein may perhaps impinge upon the accepted mitogenic actions of growth
hormone in some fashion as the rbST-treated TG fish did not exhibit the myofiber
proliferation found in the rbST-treated NTG fish. The hyperplasia found in the rbSTtreated NTG fish of the PD family was not present in the TG fish receiving hormone
treatment. There exists the possibility of an unknown interaction between the myostatin
pro-domain and an endocrine factor of the somatotropic axis or other ligand responsible
for stimulating proliferation. In this way myogenesis would proceed normally but would
not profit from the cellular proliferation afforded by somatotropin. The absence of
significant hypertrophy in the TG PD fish suggests that myostatin is not antagonistic to
the anabolic protein synthesis pathways involved in somatogenesis. Additionally, the
significantly larger cells in only the rbST-treated TG fish and not the placebo TG fish of
the ActRIIB family similarly suggests that other TGF-β ligands do not antagonize protein
accretion in trout. While it may be anticipated that an inverse relationship would exist
between myofiber number and diameter, as an increase in fiber number typically requires
individual fibers to be smaller in diameter, no such distinct trend was consistently found
in either family.
Myostatin has been clearly demonstrated to constrain proliferation (Thomas et al.,
2000) and differentiation (Langley et al., 2002; Ríos et al., 2002) in developing skeletal
muscle in mammals. It has additionally been found to suppress protein anabolism in
these cells (Taylor et al., 2001; Trendelenburg et al., 2009), entrenching its function as a
myogenic inhibitor. While the myostatin-deficient phenotype has been established in
vivo, many of the investigations concerning the mechanism of action have been derived
from in vitro findings. The physiology of myostatin regulation within the organism is
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doubtless inordinately more complex; elevated myostatin levels have conversely been
found to facilitate viability of cultured myocytes (Ríos et al., 2001). Previously believed
to restrict myogenesis by halting the recruitment and perpetuation of myosatellite cells
(McCroskery et al., 2003), myostatin is currently understood in mammals to function at
the level of the differentiated myofibers themselves by means of inhibiting protein
synthesis (Wang and McPherron et al., 2012; Lee et al., 2012; Amthor et al., 2009). The
TG fish studied here demonstrate the influence of myostatin and related TGF-βs on
muscle. However, it remains unclear whether it is the myotubes or immature myoblasts
that are the recipients of such actions. The function of myostatin in trout appears to differ
from that in mammals. In vivo, undetermined TGF-β molecules appear to inhibit
myoblast proliferation whereas myostatin alone does not, contrary to conclusions from
investigations utilizing trout myoblast cultures (Seiliez et al., 2012). The disruption of
protein synthesis by myostatin found in mammalian cells is not present in trout and,
further, a profound shift toward a growth mode dominated by hyperplasia or hypertrophy
was not found. The increased hyperplasia observed in the ActRIIB TG fish occurred
with only a moderate change in fiber dimensions. Hyperplasia and hypertrophy are
present throughout ontogeny in salmonids, serving as the predominant growth mode to
varying degrees throughout ontogeny (Johnston et al., 2011). Stratified and mosaic
hyperplasia collectively lead to somites populated by a heterogeneous collection of fibers
(Rowlerson et al., 1995; Johnston et al., 2003; Rowlerson and Veggetti, 2001). The
disruption of myostatin signaling did not appear to lead to a deviation from this mode of
growth, and the hyperplasia found in the TG ActRIIB fish failed to translate to a
significant increase in muscle mass presumably due to the same enhancement of cross-
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sectional surface area observed previously (Phelps et al., 2013). The change in surface
area that is secondary to the altered morphometrics would enable an increase in myofiber
number without a requisite increase in total muscle mass. The substantial role of
myostatin in regulating myocyte proliferation and dimensions in mammals that was not
observed in teleosts may be attributed to the determinate growth experienced by
mammals. The evolution of a finite size and restricted growth potential in these
vertebrates may necessitate a stringent regulation of myogenesis not found in species
such as salmonids that possess indeterminate growth modes.
The intricate physiology of myogenesis is regulated by myriad genes and
endocrine effectors, the muscle regulatory factors, MRFs, foremost among them; the
principal mediators of proliferation and differentiation being MyoD and myogenin,
respectively. In the current report MyoD expression was revealed to be responsive to
regulation by growth hormone as well as myostatin. In mammalian myogenesis,
myostatin activity has been demonstrated to inhibit MyoD expression in myocyte culture
(Langley et al., 2002). However, the transcriptional response in the trout studied in this
work indicated a decoupling of MyoD expression, presumably one of several paralogues,
from the myogenic functionality of the peptide. Up regulation of MyoD in the TG
individuals in both of the families was found, exceeding that in NTG fish. The presence
of a similar transcriptional response to both strategies of myostatin inhibition
demonstrates a myostatin-specific suppression of MyoD mRNA that does not require
related TGF-β peptides. Growth hormone administration similarly produced an increase
in MyoD activation. Notably, the significant increase in MyoD transcription in TG fish
was not associated with greater body size or specific growth in the TG fish; rather, TG
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fish with greater MyoD mRNA concentrations experienced growth rates parallel to NTG
fish that had received identical treatments, and did not achieve a larger ultimate size. The
up regulation of this MRF failed to increase muscularity or somatogenesis, which is
corroborated by the absence of a correlation between myocyte quantity and MyoD
expression in both families. While increased MyoD expression was associated with
instances of accelerated growth and superior mass, it does not appear to be the factor
motivating such augmentation, but instead a consequence. The regulation of MyoD by
myostatin in rainbow trout thus appears evolutionarily conserved, at least to a degree,
with that in mammals, in that MyoD regulation is subject in some fashion to regulation by
myostatin. The initiation of myogenic programs and transcriptional activation directed
by this MRF, however, does not appear to have been conserved as increased MyoD
expression did not correspond to enhanced muscle growth.
Myogenin expression failed to differ significantly between most groups, and may
reflect a similar decoupling of this MRF from the myogenic activities of fish muscle.
Within the ActRIIB family expression was not different between any of the fish, neither
genotype nor treatment regime eliciting differential activity. Minimal variation in mRNA
concentrations was similarly found within the PD family; the placebo NTG fish exhibited
greater transcription than rbST-treated NTG fish. The current data preclude a definitive
conclusion regarding the decreased myogenin transcript concentrations in some groups of
fish and not others. The absence of significant changes in myogenin transcription in two
families, each expressing a distinct inhibitory construct, suggests that myostatin and
TGF-β are not dominant regulators of this MRF. The generally accepted functions of
MyoD and myogenin in the processes of proliferation and determination in myogenic
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cells (Pownall et al., 2002) were not supported by the transcriptional activities of these
genes in either the ActRIIB or PD family.
Myostatin expression in the fish in both families raised the possibility of
autoinhibitory regulation, as well as the potential that myostatin may be requisite for fully
functional myogenesis. While a significant increase in myostatin expression was
anticipated in the PD TG fish due to the presence of the transgene construct significantly
increased expression was also detected in ActRIIB placebo TG fish relative to the NTG
placebo fish, neither of which possessed the pro-domain transgene. Disrupted myostatin
signaling in the ActRIIB TG fish might interfere with an autocrine or paracrine feedback
mechanism in the myocyctes necessary for interpreting concentrations of the bioactive
myostatin peptide; thus resulting in intensive activation of myostatin as the signaling
cascades initiated by the protein are halted and the cells are unable to detect protein
concentrations. In such an event the acknowledged endocrine actions of myostatin may
be expanded to include paracrine and/or autocrine mechanisms, as has been previously
observed (Ríos et al., 2004). Moreover, while the TG ActRIIB fish were consistently
confined to a body size significantly smaller than that of their NTG siblings, the TG PD
fish exhibited only a slightly smaller length and mass throughout. While this difference
was not significant in the PD TG fish it could suggest that myostatin is in part responsible
for rendering the NTG body form, though not to the extent that are related TGF-β
molecules. Contrasted with the more radical morphological deviation of the ActRIIB
transgenics in which additional TGF-β ligands were interfered with, it proposes a
diminished role for myostatin in maintaining non-transgenic myogenesis, and a more
arresting necessity of related TGF-βs in muscle development.
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The expression of myostatin was noticeably not down regulated in the faster
growing rbST-treated fish. In TG and NTG fish in both families myostatin expression in
the hormone-treated individuals was not significantly different from that of the placebo
fish within the same respective genotype. The absence of a down regulation of myostatin
in the context of elevated somatogenesis is contrary to findings in other teleosts (Roberts
et al., 2004; Biga et al., 2004b; Gahr et al., 2008) and humans (Oldham et al., 2009; Liu
et al., 2003). The interaction between myostatin and growth hormone in these studies
was characterized by diminished myostatin peptide concentrations in the presence of
increased growth hormone concentrations. In the current work, no such interaction
between growth hormone and myostatin transcript concentrations was observed;
however, it must also be acknowledged that while the expression of myostatin, and that of
other genes under study, was evaluated this does not absolutely reflect the translation of
these mRNAs or the functional protein concentrations present. The discordant findings
pertaining to somatotropin effects on myostatin are representative of the efforts still very
much in progress to ascertain the precise physiology of myostatin in teleosts.
Ambiguous and diametrically opposing findings for myostatin function have been
documented (Gabillard et al., in press), manifesting the intrinsic complexity and subtlety
of regulatory mechanisms. Much of the difficulty in fully resolving the workings of
myostatin may be attributed to its nearly ubiquitous expression in RBT and many other
teleost species, which contrasts with the muscle-specific expression found in mammals
(Delgado et al., 2008; Rodgers and Garikipati et al., 2008). Further impeding
understanding is the presence of multiple isoforms of genes, myostatin and the MRFs
included, due to tetraploidization of the salmonid genome (Jaillon et al., 2004). Multiple
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gene copies have enabled differential spatial and temporal expression of these genes
across diverse tissues and throughout ontogeny (Macqueen and Johnston, 2008; Rescan et
al., 1995; Rescan et al., 2001; Rescan et al., 1999; Delalande and Rescan, 1999; Roberts
and Goetz, 2003; Gabillard et al., in press). Indeed, the absence of a clearly defined
association between the expression of MyoD and myogenin, and increased somatogenesis
presented here may be a function of analysis of MRF paralogues not involved in
myogenesis, or of the inhibition of a myostatin or other TGF-β paralogue which is not
critical to muscle regulation and development. Certainly the presence of multiple
myostatin genes in salmonids (Østbye et al., 2001) represents both a challenge to the
study of all of these genes simultaneously when employing a transgenic inhibitory
mechanism, as well as an opportunity for these multiple myostatin genes to serve
disparate physiological functions. The myostatin protein inhibited in the PD family,
myostatin 1, is the primary form of the peptide present in RBT, and Thies et al. (2001)
have reported that binding by the pro-peptides of the corresponding protein within the
TGF-β is highly fidelitous. The myostatin pro-domain overexpressed in the PD TG fish
would therefore presumably effectively bind to and inhibit myostatin 1, though likely not
other forms of myostatin. Protein binding assays that could confirm the ability of the
myostatin pro-domain to re-bind the bioactive molecule and inactivate it would help to
establish with certainty that the absence of increased musculature in the PD TG fish was
not due to a failure in the mechanism employed here to inhibit myostatin. Additional
efforts, including examination of all paralogues of these genes, will be required to more
fully understand the participation of myostatin in teleostean myogenesis. In vivo
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investigations are more likely to yield physiologically relevant results as they will be able
to capture the diversity of regulation present in the intact organism.
The concurrent inhibition of myostatin, both exclusively and in conjunction with
related members of the TGF-β family of endocrine factors, in TG rainbow trout afforded
the unique opportunity to improve the understanding of myogenic physiology in a basal
teleost. Elucidating the myogenic capacity in which myostatin operates in RBT provided
additional insight into muscle development and growth along disparate evolutionary
pathways, and enabled evaluation of the conservation of myogenic regulation between
salmonids and mammals. While the physiology and regulation of myostatin in teleosts
represent evolutionary precursors to those in mammals, the function of myostatin, as well
as TGF-β molecules, appears vastly divergent in the two taxa with respect to myogenic
processes. The pronounced muscularity found in myostatin-deficient mammals was not
observed in teleosts in which the same ligands had been disrupted, indicating that
myostatin and other TGF-β ligands do not restrict skeletal muscle development in fish;
nor was exogenous somatotropin able to render a combinatorial effect alongside
myostatin inhibition. While myostatin-specific inhibition produced a phenotype barely
indistinguishable from that of NTG siblings, broader TGF-β interference resulted in a
variant body conformation. Specific members of the TGF-β protein family, likely other
than myostatin, that signal by means of the activin type IIB receptor are crucially
important to the development of axial morphology, potentially influencing somite
development. These proteins appear to operate in endocrine and paracrine fashions
beginning early in development and persisting throughout ontogeny. They additionally
function in at least a moderate capacity to constrain myocyte hyperplasia in the epaxial
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musculature, which myostatin does not. Though myostatin and the related TGF-βs
inhibited here are not involved in the regulation of growth rates, they do direct the
potential for growth. Myostatin appears minimally, if at all, requisite for achieving
growth potential, while other TGF-β ligands may restrict the capacity for growth to a
greater extent. The expression of certain myogenic regulatory genes is influenced by
TGF-β molecules, including myostatin, though this regulatory control did not increase
myogenesis. The evolutionary preservation of the peptides inhibited here suggests that
their physiological functionality has been retained, though is either not antagonistic to
myogenesis or is not muscle-specific. The disparity in myostatin biology between fish
and mammals would be expected to occur as a function of their respective physiologies.
Mammalian evolution necessitated adaptations including heterothermy, radically
different locomotory means, sweeping alterations to the proportionality and biochemistry
of muscle phenotypes, and a unique mode of growth collectively brought about by novel
and distinct selective pressures. A reduction in genome size may have additionally
wrought the specialization of genes which once had a greater array of functions.
Conversely, the somatotropic axis remained profoundly conserved amid simultaneous
modifications to the myogenic pathways. Understanding the mechanisms of processes
such as vertebrate myogenesis, and the manner in which they vary across taxa, provides
insight into important biological regulation and are instructive of the diversity of
physiologies that may arise by means of differing evolutionary trajectories and
adaptations.
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Table 1 PCR primers used for screening of transgenic F1 individuals from ActRIIB and
PD families
ActRIIB fwd
Pro-domain fwd
ActRIIB rev
PD rev

MYLC5
MYLC5
ActR6
MyoInt6

5’-CACCACTGCTCTTCCAAGTGTCA-3’
5’-CACCACTGCTCTTCCAAGTGTCA-3’
5’-TGTCCGGCAGGTGTGTAAATCTCT-3’
5’-AGAGCTGACTCCTGCATTCACGTC-3’

Table 2 PCR primers used to produce MyoD and myogenin amplicons, and for
sequencing clones
MyoD fwd
MyoD rev
Myogenin fwd
Myogenin rev

MyoD Fwd 8
MyoD Rev 9
Myogen Fwd 2
Myogen Rev 2

5’-CTGGACTCTAGACTCGTTCATG-3’
5’-ACACTTCCTGCAGGTTGTTCG-3’
5’-CTACGATCTAGAGGACAACTTCTAC-3’
5’-ACATCACCTGCAGGGACATCTAC-3’

Primers MyoD Fwd 8 & Myogen Fwd 2 contain the XbaI restriction enzyme recognition
site within their sequences. Primers MyoD Rev 9 & Myogen Rev 2 contain the SbfI
restriction enzyme recognition site within their sequences

Table 3 RT-qPCR primers used for all assays measuring transcriptional activity
ActRIIB qPCR fwd
ActRIIB qPCR rev
Myostatin PD qPCR fwd
Myostatin PD qPCR rev
MyoD qPCR fwd
MyoD qPCR rev
Myogenin qPCR fwd
Myogenin qPCR rev
GAPDH qPCR fwd
GAPDH qPCR rev

Act F230
Act R4
Myo F916
Myo R916
MyoD Fwd 4
MyoD Rev 4
Myogen Fwd 1
Myogen Rev 3
GAPDH Fwd
GAPDH Rev

5’-GCTGGCTCGACGACTTCAACT-3’
5’-CATAGGGTGGCTTGTGGTGGCG-3’
5’-ACGTGAATGCAGGAGTCAGCTCTT-3’
5’-AGGTAACCGCCAGATCATTTCCCT-3’
5’-ACACTGAAGAGATGTACGTCTAC-3’
5’-TAGTGATCCATCACCGGGTAATAG-3’
5’-AAGCTGTGCAAACGCAAGAC-3’
5’-TTCATCAGGGTGCTCCTCTTC-3’
5’-ACCACTACAACCCAATCAACAGCAA-3’
5’-TCGATGAAGGGATCGTTGATGGC-3’
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Figure 1. Fork lengths of fish in the ActRIIB family at each of the time points.
Comparisons were made on the basis of genotype and hormone treatment at each time. *
indicates a significant difference between treatment groups within genotype; ** indicates
a significant difference between genotypes within treatment type.

Figure 2. Mass of fish in the ActRIIB family at each of the time points. Comparisons
were made on the basis of genotype and hormone treatment at each time. * indicates a
significant difference between treatment groups within genotype; ** indicates a
significant difference between genotypes within treatment type.
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Figure 3. Condition factor of ActRIIB fish at each of the time points. Comparisons were
made on the basis of genotype and hormone treatment at each time. * indicates a
significant difference between treatment groups within genotype; ** indicates a
significant difference between genotypes within treatment type.

Figure 4. Fork length of fish in the PD family at each of the time points. Comparisons

were made on the basis of genotype and hormone treatment at each time. * indicates a
significant difference between treatment groups within genotype.
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Figure 5. Mass of fish in the PD family at each of the time points. Comparisons were
made on the basis of genotype and hormone treatment at each time. * indicates a
significant difference between treatment groups within genotype.

Figure 6. Condition factor of PD fish at each of the time points. Comparisons were
made on the basis of genotype and hormone treatment at each time. * indicates a
significant difference between treatment groups within genotype.
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Figure 7. Specific growth rate determined for fork length in the ActRIIB family in each
of the intervals between successive time points. Comparisons were made on the basis of
genotype and hormone treatment within each interval. * indicates a significant difference
between treatment groups within genotype.

Figure 8. Specific growth rate determined for mass in the ActRIIB family in each of the
intervals between successive time points. Comparisons were made on the basis of
genotype and hormone treatment within each interval. * indicates a significant difference
between treatment groups within genotype.
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Figure 9. Specific growth rate determined for fork length in the PD family in each of the
intervals between successive time points. Comparisons were made on the basis of
genotype and hormone treatment within each interval. * indicates a significant difference
between treatment groups within genotype.

Figure 10. Specific growth rate determined for mass in the PD family in each of the
intervals between successive time points. Comparisons were made on the basis of
genotype and hormone treatment within each interval. * indicates a significant difference
between treatment groups within genotype.
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Figure 11. Myofiber number in ActRIIB family. * indicates a significant difference
between treatment groups within genotype; ** indicates a significant difference between
genotypes within treatment type; *** indicates a significant interaction between genotype
and hormone treatment.

Figure 12. Myofiber diameter (µM) in the ActRIIB family. * indicates a significant
difference between treatment groups within genotype; ** indicates a significant
difference between genotypes within treatment type; *** indicates a significant
interaction between genotype and hormone treatment.
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Figure 13. Myofiber number in the PD family. * indicates a significant difference between
treatment groups within genotype; ** indicates a significant difference between genotypes within
treatment type; *** indicates a significant interaction between genotype and hormone treatment.

Figure 14. Myofiber diameter (µM) in fish in the PD family. * indicates a significant
difference between treatment groups within genotype; ** indicates a significant
difference between genotypes within treatment type; *** indicates a significant
interaction between genotype and hormone treatment.
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Figure 15. Expression of ActRIIB transgene construct in TG ActRIIB fish. Construct
expression was normalized to gapdh. Expression was not significantly different between
treatments. NTG fish are not represented as they do not contain the ActRIIB transgene
construct.

Figure 16. Myostatin pro-domain expression in the ActRIIB family normalized to gapdh.
* indicates a significant difference between treatment groups within genotype; **
indicates a significant difference between genotypes within treatment type.
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Figure 17. MyoD expression normalized to gapdh in the ActRIIB fish. * indicates a
significant difference between treatment groups within genotype; ** indicates a
significant difference between genotypes within treatment type.

Figure 18. Expression of myogenin, normalized to gapdh, in the ActRIIB family. None
of the groups differed significantly from one another.
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Figure 19. Expression of the myostatin pro-domain normalized to gapdh in the PD
family. * indicates a significant difference between treatment groups within genotype; **
indicates a significant difference between genotypes within treatment type.

Figure 20. MyoD expression normalized to gapdh in the PD family. * indicates a
significant difference between treatment groups within genotype; ** indicates a
significant difference between genotypes within treatment type.
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Figure 21. Expression of myogenin in the PD family normalized to gapdh. * indicates a
significant difference between treatment groups within genotype; ** indicates a
significant difference between genotypes within treatment type.
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APPENDIX A: CORRELATION ANALYSES
The data and results contained herein were collected from the original study and
are intended to serve as supplemental information within the context of the findings
presented in the thesis.
The expression and histological data were utilized in correlation analyses to glean
putative relationships between the expression of the various genes of interest, as well as
some that may have existed between the expression of such genes and the mitotic and/or
growth physiology of the epaxial myocytes. Correlations were carried out between the
expression of MyoD and myostatin, myogenin and myostatin, and MyoD and myogenin in
both the ActRIIB and PD families. Additionally, in the ActRIIB family, correlations
between the ActRIIB construct and myostatin expression levels were performed; this
could only be done for the TG fish as the NTG individuals lacked the construct entirely.
In both families myostatin expression was regarded as indicative of levels of the
transcript which encodes the myostatin pro-peptide in which the pro-domain and
bioactive portion remain bound prior to post-translational processing.
Along with correlations relating expression levels were those comparing myofiber
number and diameter for both families. Myofiber number and the expression of MyoD
were correlated for all experimental groups in the ActRIIB and PD families. The number
of samples available for comparisons (N = 10 for gene expression correlations, N = 6 for
histological correlations) instructed the use of both Pearson and Spearman correlations to
account for relationships that had the potential to be obscured by the nature of the data
sets. Those correlations reported as significant, however, are only noted as such in those
instances in which the test most appropriate to the distribution of the data set revealed a
significant coefficient.
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Relatively few of the correlations analyzed in either of the families proved
significant. In both the rbST-treated and placebo ActRIIB TG fish there was a positive
relationship between the expression of the ActRIIB construct and myostatin which was
not significant (Fig. 22). The coefficients for comparisons of MyoD and myostatin
expression ranged from weak to moderate, none of which achieved significance (Fig. 23).
The coefficients comparing myogenin and myostatin for all groups in the ActRIIB family
indicated fairly weak correlations, none of which were significant (Fig. 24). Despite
fluctuations in magnitude of the correlations between the various groups, none of the
comparisons relating MyoD and myogenin expression proved significant in the ActRIIB
family (Fig. 25).
The relationship between the number of myofibers and their diameters in the
ActRIIB fish was defined in all groups by an inverse relationship in which individuals
with a greater number of myofibers were those with smaller diameter fibers., Correlations
between diameter and number were significant in placebo TG fish (r2 = -0.90) and the
rbST-treated NTG fish (r2 = -0.89) (Fig. 26). Myofiber number and MyoD expression,
however, were not found to be significantly correlated in these fish (Fig. 27).
In the PD fish MyoD expression was significantly related to that of myostatin in
the placebo TG fish (rs2 = 0.77) and the placebo NTG fish (r2 = 0.75), with an increase in
expression of MyoD corresponding to increased expression of myostatin (Fig. 28).
Myogenin expression increased significantly in accord with myostatin in the rbST-treated
TG fish (r2 = 0.67); however, this significance was exclusive to this group in the PD fish
(Fig. 29). As in the ActRIIB fish, the relationship between MyoD and myogenin
transcription in the PD fish was not significant in any of the fish (Fig. 30).
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The TG rbST-treated and placebo fish exhibited a significant inverse relationship
(r2 = -0.84 and r2 = -0.98, respectively) between myocyte number and diameter, i.e.,
increased myofiber diameters were found in fish with fewer numbers of fibers (Fig. 31).
MyoD expression was not significantly correlated with myocyte number in the PD
family, similar to what had been observed in the ActRIIB fish (Fig. 32).
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Table 4 Pearson (r2) and Spearman (rs2) correlations for parameters in the ActRIIB
family. * indicates a significant correlation; correlations are denoted as significant for
those tests which were most appropriate to the data set.
Correlation

Group

r2

p

rs2

p

ActRIIB-Myostatin (PD)
expresion

rbST-treated TG
placebo-treated TG

0.47
0.21

0.17
0.56

0.54
0.18

0.11
0.63

MyoD-Myostatin (PD)
expression

rbST-treated TG
placebo-treated TG
rbST-treated NTG
placebo-treated NTG

-0.47
0.35
0.63
0.37

0.17
0.33
0.05
0.29

-0.47
0.42
0.59
0.25

0.17
0.23
0.07
0.49

Myogenin-Myostatin (PD)
expression

rbST-treated TG
placebo-treated TG
rbST-treated NTG
placebo-treated NTG

0.35
0.28
-0.02
0.5

0.32
0.43
0.95
0.14

0.21
0.26
-0.13
0.22

0.56
0.47
0.73
0.53

MyoD-Myogenin expression

rbST-treated TG
placebo-treated TG
rbST-treated NTG
placebo-treated NTG

-0.50
0.55
0.36
0.79

0.14
0.10
0.31
0.01

-0.59
0.59
0.25
0.47

0.07
0.07
0.49
0.17

Myofiber number-MyoD
expression

rbST-treated TG
placebo-treated TG
rbST-treated NTG
placebo-treated NTG

-0.26
-0.08
0.19
-0.75

0.62
0.86
0.72
0.08

-0.03
0.14
0.43
-0.14

0.96
0.79
0.40
0.79

Myofiber number-Myofiber
diameter

rbST-treated TG
placebo-treated TG
rbST-treated NTG
placebo-treated NTG

-0.55
-0.9
-0.89
-0.33

0.26
0.01*
0.02*
0.52

-0.43
-0.49
-0.77
-0.54

0.40
0.33
0.07
0.27
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Table 5 Pearson (r2) and Spearman (rs2) correlations for parameters in the PD family.
* indicates a significant correlation; correlations are denoted as significant for those tests
which were most appropriate to the data set.
Group

r2

p

rs2

p

MyoD-Myostatin (PD)
expression

rbST-treated TG
placebo-treated TG
rbST-treated NTG
placebo-treated NTG

0.29
0.35
0.36
0.75

0.42
0.32
0.30
0.01*

0.3
0.77
0.41
0.62

0.40
0.01*
0.24
0.05

Myogenin-Myostatin (PD)
expression

rbST-treated TG
placebo-treated TG
rbST-treated NTG
placebo-treated NTG

0.67
0.4
0.04
0.06

0.03*
0.26
0.90
0.88

0.61
0.35
0.25
0.21

0.06
0.33
0.49
0.56

MyoD-Myogenin expression

rbST-treated TG
placebo-treated TG
rbST-treated NTG
placebo-treated NTG

-0.12
0.05
0.22
0.06

0.75
0.88
0.54
0.88

0.04
0.04
0.36
0.05

0.91
0.91
0.31
0.88

Myofiber number-MyoD
expression

rbST-treated TG
placebo-treated TG
rbST-treated NTG
placebo-treated NTG

0.53
0.09
-0.16
-0.41

0.27
0.87
0.76
0.43

0.49
0.26
-0.14
-0.20

0.33
0.62
0.79
0.70

Myofiber number-Myofiber
diameter

rbST-treated TG
placebo-treated TG
rbST-treated NTG
placebo-treated NTG

-0.84
-0.98
0.19
-0.80

0.04*
<0.00
0.71
0.05

-0.60
-0.89
0.09
-0.60

0.21
0.02*
0.87
0.21

Correlation
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Figure 22. Expression of myostatin and ActRIIB transgene construct in rbST-treated and
placebo TG ActRIIB fish. Neither treatment group exhibited a significant correlation
between expression of the two genes.

73

Figure 23. MyoD and myostatin pro-domain expression in the ActRIIB family.
Correlations were not significant in any of the groups.
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Figure 24. Expression of myostatin pro-domain and myogenin in the ActRIIB family.
There were no significant relationships in the expression of the two genes in any of the
groups.
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Figure 25. Expression of MyoD and myogenin in the ActRIIB family. None of the
groups exhibited a significant relationship between the transcription of the two genes.
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Figure 26. Myofiber number and diameter in the ActRIIB family. In all groups
increasing numbers of fibers were correlated with a smaller myofiber diameter. The
relationship between number and diameter was significant in the placebo TG fish and
NTG rbST-treated fish.
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Figure 27. Myofiber number and MyoD expression in the ActRIIB family. None of the
groups exhibited a significant relatinship between gene expression and myofiber number.
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Figure 28. MyoD and myostatin transcription levels in the PD family. Transcription of
the two genes was significantly correlated in the placebo fish of both genotypes, though
not in the rbST-treated fish.
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Figure 29. Myogenin and myostatin expression in the PD family. Expression of the two
genes was significantly correlated in only the TG rbST-treated fish.
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Figure 30. MyoD and Myogenin expression in the PD fish. The relationship between the
two genes was not significant in any of the groups.
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Figure 31. Myofiber number and diameter in the PD family. Fiber number was
significantly related to fiber diameter in all TG fish.
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Figure 32. Myofiber number and MyoD expression in the PD family. Gene expression
was not significantly correlated to myofiber number in any of the groups.
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APPENDIX B: LITERATURE REVIEW
Myostatin
The transforming growth factor-β (TGF-β) cytokines comprise a superfamily of
closely related endocrine factors which are involved in the regulation of an array of
cellular processes which mediate growth processes in vertebrates. Despite a number of
shared characteristics in their structure and maturation, the peptides within this
substantial group of related proteins instruct physiological processes in a suite of different
cell types and tissues. They function by binding to an assortment of cellular receptors,
and initiate intracellular cascades mediated by a still greater number of signaling
molecules and transcription factors; they are also subject to regulation themselves in a
number of capacities by a variety of mechanisms. One of the members of the TGF-β
superfamily, myostatin, has been prolifically and intensively studied as it serves to
negatively regulate skeletal muscle growth in mammals (McPherron et al., 1997; Rodgers
and Garikipati, 2008). Myostatin has monopolized research efforts as it has implications
in the biomedical, agricultural, regenerative medicine, and pathology fields (Joulia-Ekaza
and Cabello, 2006; Rodgers and Garikipati, 2008; Lee, 2004).
Elucidation of the structure of the myostatin proteins in bovine species revealed
that they contained a number of the characteristics which distinguish, and are shared by,
TGF-β ligands (McPherron and Lee, 1997; McPherron et al., 1997). Myostatin, similar
to other TGF-β ligands, contains a secretion-directing domain, a conserved RSRR
sequence directing proteolytic cleavage and processing, and a highly conserved carboxyterminal domain which is defined by the presence of a number of cysteine residues
(McPherron et al., 1997; de Caestecker, 2004). The unwavering patterning of these
cysteine residues is crucial to the ability of myostatin to assume a functional
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conformation and forms a cysteine knot through disulfide bonds joining these residues
(McPherron et al., 1997; McPherron and Lee, 1997).
Myostatin, unlike some of the related TGF-βs, is initially synthesized as an
inactive precursor in which the biologically active C-terminal domain is bound to the
amino-terminal pro-domain portion of the peptide (sometimes referred to as a latency
associated protein, LAP) as well as other proteins, including the latent TGF-β binding
protein (LTBP) in a latent complex (Lee and McPherron, 2001; de Caestecker, 2004;
Thomas et al., 2000; Munger et al., 1997). TGF-β ligands retained within this latent
complex appear to be bound to the extracellular matrix following secretion from the cell,
and proteolytic or non-proteolytic cleavage by factors such as plasmin or
thrombospondin, respectively, may free the ligand, at which point it would remain
complexed with the pro-domain region (Munger et al., 1997; Lee and McPherron, 2001).
Myostatin appears, even in its inactive form, to dimerize by means of disulfide linkages,
and subsequent proteolytic cleavage at the RSRR sequence site by BMP-1 (bone
morphogenetic protein)/tolloid metalloproteinase family members releases the C-terminal
homodimer active peptide from the N-terminal pro-domain, at which point the 376
residue C-terminal active domain is rendered physiologically viable (McPherron et al.,
1997; Thomas et al., 2000; Lee and McPherron, 2001; Lee, 2004). The functionality of
myostatin relies on its release from the latency complex as well as the N-terminal prodomain (Lee and McPherron, 2001); Thomas et al. (2000) established that the latency
complex-associated form of myostatin, as well as the inactive, pro-domain-bound form
are contained within myoblasts, while the smaller, mature myostatin protein is not. The
mature protein was instead located in the skeletal muscle, indicating it was secreted
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following release from the pro-domain, and likely defining myoblasts as the site of
proteolytic processing (Thomas et al., 2000).
Myostatin exerts its regulatory control of mammalian skeletal muscle through
signaling cascades and mechanisms employed by most, if not all, TGF-β ligands
(Kemaladewi et al., 2011; Lee, 2004; de Caestecker, 2004; Lee, 2007; Derynck and
Zhang, 2003). There are two, highly similar, receptor classes (type I and type II) which
bind circulating myostatin as well as other TGF-β ligands (Lee, 2007; de Caestecker,
2004; Derynck and Zhang, 2003). The extracellular binding domain of both receptor
types is defined by a three-finger toxin fold conformation, and both types possess both a
single membrane-spanning domain and intracellular serine-threonine kinase domain
(Derynck and Zhang, 2003; de Caestecker, 2004). The type I and type II receptor classes
differ with respect to the sequence of their kinase domains, as well as the existence of a
defined glycine-serine sequence (commonly referred to as the GS box) found on the type
I receptors but absent in the type II receptors; this GS box remains crucial for type I
receptor activation (de Caestecker, 2004; Massagué, 2000).
The two classes of TGF-β receptors commonly exist in homodimeric associations
within the cell membrane when not bound by ligands; however, myostatin binding of the
type II receptor inspires association with the type I receptor (also referred to as the
Activin-like kinase, ALK) ( Derynck and Zhang, 2003). Myostatin appears to
preferentially bind the type II receptor initially, specifically the Activin type IIB receptor
as opposed to the type IIA receptor (Lee and McPherron, 2001; Lee, 2007; Derynck and
Zhang, 2003). As binding of the C-terminal active myostatin domain induces association
with the type I receptor (ALK4 in myocytes, Kemaladewi et al., 2011) a heteromeric
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receptor tetramer complex is formed, and the intracellular kinase domain of the type II
receptor transphosphorylates the GS box of the type I receptor, activating it (Lee, 2007;
Massagué, 2000). The activated GS domain subsequently phosphorylates intracellular
receptor Smad (R-Smad) proteins, in the case of myostatin signaling Smad2 and Smad3
are phosphorylated and subsequently associate with a coeffector, Smad4 (Langley et al.,
2002; Liu et al., 2001; Derynck and Zhang, 2003; Ge et al., 2011). The activated Smads
translocate to the nucleus where they suppress transcription of myogenic genes including
MyoD and Pax-3, functionally interacting with and inhibiting the actions of myogenic
transcription factors such as MyoD, and precluding muscle growth (Liu et al., 2001;
Derynck and Zhang, 2003; Amthor et al., 2004).
The regulation of myogenesis by myostatin is a function of the peptide’s
disruption of cell cycle progression, as well as functionally mediating myoblast and
satellite cell populations, and differentiated muscle tissue, by means of governing
transcriptional activity and mitogenic pathways (Thomas et al., 2000; Joulia-Ekaza and
Cabello, 2006; Wang and McPherron, 2012; Amthor et al., 2009; Taylor et al., 2001;
Langley et al., 2002; McCroskery et al., 2003; Garikipati and Rodgers, 2012; Liu et al.,
2001). Myostatin was demonstrated to inhibit myocyte proliferation in vitro, an effect
which could be reversed with cessation of myostatin administration to the cell cultures
(Thomas et al., 2000; Talyor et al., 2001). Regulation of the cell cycle was found to be
mediated by the expression of genes which serve as mitotic effectors, which were
influenced by myostatin signaling (Thomas et al., 2000). Advancement of cells from the
G1 to the S phase during mitosis is governed in large part by the enzymatic activities of
cyclin-dependent kinases (CDKs) complexed with specific cyclins, the actions of which
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are in turn modulated by CDK inhibitors such as p21 (Thomas et al., 2000). The role of
CDKs in the cell cycle remains essential as they phosphorylate the retinoblastoma (Rb)
protein, thereby inactivating it, as the Rb protein in its hypophosphorylated form halts
mitotic progression (Thomas et al., 2000). Notably, Thomas et al. (2000) found that
administering myostatin to cell cultures concomitantly upregulated p21 and reduced both
the activity and concentration of cyclin E-CDK2 complexes. Moreover, myostatin was
found to upregulate p21 solely, rather than any of the other CDK inhibitors, and increase
concentrations of hypophosphorylated Rb protein (Thomas et al., 2000).
Myostatin, therefore, was suggested to inhibit muscle growth at least in part
through its regulation of myoblast proliferation (Thomas et al., 2000). These
investigators additionally introduced myostatin to myocyte cultures derived from wild
type and Belgian Blue cattle, which exhibit dramatically increased skeletal muscle, and
demonstrated that cells from both cattle breeds were inhibited by myostatin. These data
confirm that in the Belgian Blue cattle the increased muscling is the result of a
nonfunctional myostatin protein rather than a receptor, as deregulation of the receptor
would preclude growth inhibition of Belgian Blue cell cultures by myostatin.
Myostatin, in addition to disrupting the mitotic progression of myoblasts, was
found to constrain protein synthesis in C2C12 cell cultures (Taylor et al., 2001). These
effects were not attributable to apoptotic events, though the reduction in protein
aggregation may have been secondary to reduced muscle accretion generally as a result
of myostatin’s actions (Taylor et al., 2001). Antagonism of muscle growth by myostatin
has additionally been found to result from perturbation of cellular differentiation
(Langley et al., 2002; Liu et al., 2001). Transcriptional repression by myostatin was
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demonstrated to be mediated by Smad3, which is able to intrude upon the functionality of
the transcription factor MyoD by means of direct interaction with the basic Helix-LoopHelix (bHLH) motif of the protein (Liu et al., 2001; Langley et al., 2002). Down
regulation of genes specifying the myogenic lineage, such as myogenin, and disruption of
MyoD activity and expression, effectively hinder the pathways leading to lineage
specification and differentiation (Langley et al., 2002; Liu et al., 2001).
Muscle satellite cells, myogenic stems cells which may be recruited in the event
of post-natal muscle repair, and perhaps for growth, are also subject to regulation by
myostatin (McCroskery et al., 2003; Wang and McPherron, 2012). While myostatin was
demonstrated to negatively influence replenishment of satellite cell populations, and
suppress activation of these cells (McCroskery et al., 2003) it may be that muscle growth
relies minimally, or not at all, on recruitment of these cells to increase tissue mass (Wang
and McPherron, 2012; Amthor et al., 2009). Muscle growth was found to result not from
hyperplasia subsequent to satellite cell activation, but rather from hypertrophy of existing
myofibers (Wang and McPherron, 2012; Amthor et al., 2009). Only minimal satellite
cell activation was found in myostatin-inhibited adult mice, and the hypertrophic growth
that took place occurred predominantly within existing myofibers, without the
recruitment of latent cells; thus indicating that myostatin acts more extensively on fully
differentiated tissue (Wang and McPherron, 2012).
While these data appear to conflict with those concerning the inhibition of
myoblast proliferation by myostatin the seemingly disparate mechanisms of myostatin
regulation may not be entirely mutually exclusive. It may be that myostatin functions in
distinct capacities to regulate muscle development at various points throughout ontogeny.
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Myostatin may operate in a temporally delimited fashion throughout the life history of
the organism; wherein the mechanisms employed for the regulation of muscle growth in
embryonic, or early post-natal development, may differ from those that regulate growth
later. Conceivably, restraining proliferation earlier in development to limit muscle
growth may give way to the inhibition of protein synthesis in fully differentiated tissue;
alternatively, there may exist some overlap or synchronicity of these events.
Physiological regulation of myostatin is both dynamically structured and versatile,
occurring by means of numerous mechanisms and thereby enabling precise control of its
signaling and actions. Myostatin is beholden to both intracellular and extracellular
regulatory effectors, which may act on the molecule specifically, or rather as only one of
a multitude of ligands moderated by a particular entity. Additionally, the regulation of
myostatin may occur along the signaling pathway, while present in circulation, or at the
transcriptional level. Decorin, a proteoglycan which associates with the collagen fibrils
of the extracellular matrix, and which is known to regulate TGF-β ligands, is profoundly
capable of regulating myostatin and its actions (Miura et al., 2006; Kishioka et al., 2007;
Zhang et al., 2012). Proliferation of C2C12 cells overexpressing decorin exhibited
increased proliferation rates and accelerated progression through the cell cycle, as well as
improved rates of differentiation (Kishioka et al., 2007; Miura et al., 2006). Moreover,
myostatin binding by decorin appears to interfere with an autoendocrine inhibitory
feedback mechanism employed by myostatin in which the protein binds the gene
promoter to modify its expression (Kishioka et al., 2007).
Myostatin-null mice were found to have increased decorin expression, which led
to contrasting effects on healing within different tissues following induced wounding
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(Zhang et al., 2012; McCroskery et al., 2005). While satellite cell activation and
migration to the wound site was increased, and muscle repair was augmented by
enhanced macrophage enlistment and consequently improved inflammatory response in
these mice, healing of the dermal and epidermal layers was antagonized in the absence of
myostatin (McCroskery et al., 2005; Zhang et al., 2012). This was attributed to the upregulation of decorin, which subsequently disrupted the actions of other TGF-βs in the
skin which are required for repair, such as those directing keratinocytes; which
collectively point to disparate tissue-specific roles for myostatin (Zhang et al., 2012).
Myostatin inhibition can additionally be accomplished by the pro-domain of the
endogenous peptide, as well as other endocrine factors, and receptor regulation. When
bound to the N-terminal pro-domain portion of the peptide, the activity of the C-terminal
active domain is suppressed and it is only following cleavage from the pro-domain that
the mature molecule can become active (Lee and McPherron, 2001). The pro-domain is
therefore able to quell myostatin levels, serving as a primary control mechanism of the
concentration of the physiologically active ligand. An array of other molecules bind
myostatin in circulation, or locally within the muscle tissue, some of which bind the
mature peptide and others of which bind the latent form; some factors may bind both
forms (Joulia-Ekaza and Cabello, 2006). One such molecule, follistatin, effectively binds
to and represses myostatin activity in both mammalian and non-mammalian species
(Haidet et al., 2008; Rebhan and Funkenstein, 2008; Medeiros et al., 2009; Lee et al.,
2010). The complexity and flexibility of myostatin binding is further elaborated by
molecules such as growth and differentiation factor-associated serum protein-1 (GASP1), follistatin-related gene (FLRG), titin-cap, and human small glutamine-rich
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tetratricopeptide repeat-containing protein (hSGT), which are able to variously bind
mature and/or immature myostatin in circulation and/or within the skeletal muscle
(Joulia-Ekaza and Cabello, 2006; Wang et al., 2003; Hill et al., 2002; Hill et al., 2003).
As myostatin antagonists these factors are fundamental to maintaining proper skeletal
muscle growth and homeostasis.
The mode of TGF-β receptor endocytosis has also been established as a means of
regulating the viability of TGF-β ligands (Di Guglielmo et al., 2003), myostatin
presumably among them. Cell surface TGF-β receptors internalized within clathrincoated pits are maintained and their signals faithfully transduced to intracellular receptors
(Di Guglielmo et al., 2003). Alternatively, if the receptors are endocytosed by means of
caveolin-coated caveolae the ligand-bound receptor complex is slated for degradation and
the signal fails to be transduced (Di Guglielmo et al., 2003). Intracellular regulation of
myostatin signaling may also be mediated by Smad proteins, as the translocation of the
R-Smads to the nucleus is subject to independent regulation, and inhibitory effectors such
as Smad6 and Smad7 target signaling R-Smads for degradation (Derynck and Zhang,
2003). Transcriptional and post-translational regulation of myostatin in some teleost
species may also be affected through somatotropin expression (Roberts et al., 2004;
Roberts and Goetz, 2003). In brook trout (Salvelinus fontinalus) the 5’ regulatory regions
in both myostatin alleles were found to contain a somatostatin-responsive sequence
domain, suggesting regulation by an anabolic factor at the genomic level (Roberts and
Goetz, 2003).
Myostatin functions to regulate somatic growth as a negative endocrine effector
of skeletal muscle growth in mammals (McPherron and Lee, 1997; Kambadur et al.,
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1997). Several mammalian species possessing mutations in the myostatin gene exhibit a
dramatic muscular phenotype, commonly referred to as double-muscled breeds (Clop et
al., 2006; Mosher et al., 2007; McPherron and Lee, 1997). The increased muscling in
domesticated breeds such as Texel sheep, Piedmontese and Belgian Blue cattle, and
“bully” whippets has been attributed to nonfunctional myostatin in the skeletal muscle
(Clop et al., 2006; Mosher et al., 2007; Kambadur et al., 1997; McPherron and Lee,
1997). Texel sheep were found to possess a mutation in the 3’ untranslated region (3’
UTR) of the myostatin gene that gave rise to a site which could be exploited by
microRNAs, leading to transcript degradation and failed signaling (Clop et al., 2006).
The phenotype observed in the Belgian Blue cattle was found to result from a frameshift
in the third exon due to an 11-nucleotide deletion, which led to truncation of the protein
and the absence of nearly the complete active portion; by contrast the Piedmontese
phenotype is caused by the loss of one of the cysteine residues essential to the formation
of the cysteine knot in the C-terminal (McPherron and Lee, 1997; Kambadur et al., 1997).
Myostatin deregulation attributable to a mutant allele and leading to muscle enhancement
has been discovered in humans as well (Schuelke et al., 2004).
The physiological administration of myogenic processes by myostatin that have
been observed in domesticated mammals, and the phenotypes generated by its
deregulation, have become better understood through experimental manipulation of the
peptide. Myostatin-null mice exhibit significantly greater skeletal muscle mass, and a
phenotype reminiscent of the double-muscling seen in myostatin-deficient cattle
(McPherron and Lee, 1997; McPherron et al., 1997; Yang et al., 2001; Zhu et al., 2000;
Lee, 2007; Thies et al., 2001; Lee and McPherron, 2001). Transgenic mice expressing
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the myostatin antagonist follistatin, as well as those expressing a dominant negative
isoform of the Activin IIB receptor (ActRIIB), part of the heterodimeric receptor
complex through which myostatin signals, exhibited increased muscle mass due to both
hyperplastic and hypertrophic skeletal muscle growth (Lee and McPherron, 2001). Zhu
et al. (2000) generated transgenic mice expressing a dominant negative isoform of the
endogenous myostatin protein, though discovered that the muscle growth observed was
the result of hypertrophy rather than hyperplasia; they suggested that the level or method
of myostatin knockdown in this approach may account for the difference in the mode of
muscle enhancement.
Increased myogenesis was also achieved in transgenic models using follistatin and
the pro-domain region of the endogenous myostatin peptide (Yang et al., 2001; Thies et
al., 2001; Lee et al., 2010; Lee, 2007). Transgenic expression of the myostatin prodomain in a murine model led to increased hypertrophic growth in a manner proportional
to the level of construct expression, though it was acknowledged that the increases were
more moderate compared to those observed in myostatin knockout mice (Yang et al.,
2001). Thies et al. (2001) demonstrated the specificity of the myostatin pro-domain in its
actions on myostatin, suggesting that despite the presence of a pro-domain region in other
TGF-β ligands the crosstalk between these inhibitory N-terminal domains and the various
ligands of the superfamily may be minimal or nonexistent. Furthermore, they observed a
differential regulation by myostatin of the factors involved in glycolytic and oxidative
fiber development; factors involved in glycolytic fiber development such as MyoD were
up-regulated in myostatin null mice, while those involved in oxidative fiber growth were
conversely suppressed.
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In vivo analysis found myostatin complexed with the pro-domain in circulation,
while FLRG was similarly able to inhibit myostatin activity (Hill et al., 2002). In the
chick, myostatin down-regulated myogenic factors such as Myf-5 and Pax-3
embryonically (Amthor et al., 2002). Follistatin effectively bound myostatin, halting
down-regulation of these myogenic genes, and colocalized with myostatin to some extent
during embryonic limb bud development in the chick; suggesting that these two
contrasting signaling effectors perhaps work somewhat cooperatively, if in opposition, to
structure muscle tissue embryonically (Amthor et al., 2004).
While myostatin has come to be understood as indispensable in mammalian
myogenesis it does not appear to function unilaterally. Regulatory molecules such as
follistatin are able to bind not only myostatin, but also other TGF-β ligands; making it a
broadly competent effector capable of potentially binding other myogenic antagonists
(Lee et al., 2010). It has also been suggested that Activin A, another TGF-β family
member, may work in addition to myostatin to regulate muscle development (Lee et al.,
2010). To this end, muscle growth exceeding that found in myostatin-null mice was
accomplished as TGF-β ligands were simultaneously inhibited alongside myostatin (Lee,
2007: Lee et al., 2005). Myostatin-null mice bred with mice overexpressing follistatin
were able to achieve greater muscle mass than either of the singly transgenic individuals
(Lee, 2007). Similarly, the introduction of a soluble ActRIIB receptor against a
myostatin-null genetic background generated muscle mass beyond myostatin knockout
independently (Lee et al., 2005). These data collectively point to the involvement of
other TGF-β, or even unrelated, ligands in mediating the physiology of mammalian
muscle growth.
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The characterization and understanding of myostatin function in mammals does
not extend into other phylogenetic groups. Myostatin has been discovered in a number of
teleost species, in many cases multiple gene copies have been determined and their
tissue-specific expression resolved (Roberts and Goetz, 2001; Rodgers et al., 2001;
Østbye et al., 2007; Radaelli et al., 2003; Rescan et al., 2001). Unlike mammals, in
which myostatin is expressed in skeletal muscle tissue and very few others, teleosts
express myostatin in a wide variety of tissues (Rescan et al., 2001; Radaelli et al., 2003;
Roberts and Goetz, 2001). Differential expression of the isoforms in the tissues is
observed in a number of species; the expression of myostatin1 was ubiquitous in the
tissues examined, while myostatin2 expression was limited to the brain and skeletal
muscle (Radaelli et al., 2003; Rsecan et al., 2001; Roberts and Goetz, 2001). The
expression profiles of the two genes were found to differ between oxidative and
glycolytic muscle tissue as well (Roberts and Goetz, 2001).
Attempts to resolve the precise physiological function of myostatin in fish have
been frustrated by the presence of multiple isoforms and expression profiles which
deviate widely from those in mammals, characteristics owing to the evolutionary distance
between these lineages. Some of these disparities may be accounted for by the multiple
genome duplication events which occurred within teleosts over the course of their
evolution, and which brought about multiple gene paralogues (Jaillon et al., 2004;
Amores et al., 1998; Rescan et al., 2001). Such duplication events enable evolution to
act, perhaps independently, on these distinct isoforms, wherein some may retain their
ancestral function while others are able to elaborate novel utilities and transcripts. The
human, rat, mouse, baboon, porcine, bovine, chicken, turkey, ovine, and zebrafish (Danio
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rerio) predicted amino acid sequences all contain the conserved proteolytic cleavage site,
and the active domain of the molecule in zebrafish shares substantial similarities (88%)
with those of more derived vertebrates (McPherron and Lee, 1997; Rescan et al., 2001).
The sequence and structural conservation found in myostatin across taxa may
belie a functional incongruity which exists between its physiological role in teleosts and
other vertebrates. Experimental inhibition of myostatin in bony fish has led to alterations
in the musculature and myogenic processes, but may not signal a substantial role for this
ligand in the muscle regulation of these fish (Xu et al., 2003; Rebhan and Funkenstein,
2008; Seiliez et al., 2012; Garikipati and Rodgers, 2012; Medeiros et al., 2009; Martin
and Johnston, 2005). Muscle growth in teleosts occurs in a manner distinct from that in
mammals, and a number of bony fish possess an indeterminate growth potential (Rescan,
2005; Xu et al., 2003; Johnston et al., 2003). In teleosts both mosaic and stratified
hyperplasia contribute to muscle growth at different points in ontogeny (Rescan, 2005;
Johnston et al., 2003). The dorsal and ventral germinal regions of the developing
myotome undergo a stratified hyperplasia as spatially distinct increases in fiber number
occur at different points along the dorso-ventral axis of the somite (Rescan, 2005). Later
in development, as well as postembryonically, this stratification gives way to hyperplastic
growth occurring throughout the myotome as dispersed myogenic progenitor cells either
continue proliferating to form new fibers, or augment the structure of existing fibers
(Rescan, 2005; Johnston et al., 2003). In this way the architecture of the myotome is
defined by a heterogeneous population of fibers (Rescan, 2005; Johnston et al., 2003).
Expression of the myostatin pro-domain in transgenic zebrafish led to minimal
increases in the musculature which were attributed to stratified, but not mosaic,

97

hyperplasia (Xu et al., 2003). These findings corresponded with differential temporal
expression of myostatin in zebrafish, which was minimal in the embryos (Xu et al.,
2003). These results were found, however, in a species with determinate growth, and
may not be applicable to indeterminately growing fishes. While follistatin and prodomain constructs were both found to efficiently bind gilthead seabream (Sparus
auratus) myostatin this was found in vitro and the impacts on muscle development were
not elucidated (Rebhan and Funkenstein, 2008). Similarly, myostatin was found to
promote differentiation in rainbow trout (Oncorhynchus mykiss) cells, whereas it is
inhibitory to differentiation in mammalian cells (Garikipati and Rodgers, 2012).
Rainbow trout overexpressing follistatin had increased muscling as a result of
hyperplasia, and exhibited a distinctly muscled phenotype which may be caused by
interference with myostatin, or other TGF-β ligands (Medeiros et al., 2009).
The diversity of function that exists for myostatin and TGF-β ligands may be
accounted for by the extensive suite of regulatory mechanisms that may influence these
endocrine factors, and may potentially underlie some of the interspecific differences in
their functions. The TGF-β signaling cascade is initiated by ligand binding to the
extracellular domain of the TGF-β receptors, which elicits the assembly of a receptor
complex (Derynck and Zhang, 2003). However, the particular receptor components
comprising the receptor complex can vary depending upon the cellular context, and can
either bind multiple ligands, or initiate different signaling cascades when bound by the
same ligand (de Caestecker, 2004; Derynck and Zhang, 2003; Kemaladewi et al., 2011).
This diversity creates a vast number of potentials for signaling and gene expression in
different tissues and at different points in development. The intracellular signaling R-
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Smads may additionally associate in various conformations; the (Mad Homology) MH1
and MH2 domains of the Smad proteins are able to associate with sequence-specific
transcription factors, and their C-terminal domains draw in transcriptional coactivators
(Derynck and Zhang, 2003). Additionally, sequences within the receptors, and the MH2
domains of the R-Smads confer binding specificity, and R-Smad activation relies on
phosphorylation of serine residues within the C-terminal SSXS sequence (Massagué,
2000). Smads are subject to independent regulation and degradation by Smurf1 and
Smurf2 (Smad-ubiquitination-regulatory factor); and complexes such as SARA (Smad
anchor for receptor activation) and TRAP-1 (TGF-β-receptor-associated protein)
participate in R-Smad-receptor association (Derynck and Zhang, 2003). Moreover, TGFβ ligands can directly activate MAPK (mitogen activated protein kinase) pathways
without Smad intermediaries (Derynck and Zhang, 2003). Master transcription factors
present in different cell types were discovered to bind Smad 3 following TGF-β
activation and direct the expression of cell-specific genes within these tissues,
accentuating the essential nature of the cellular context in which this signaling occurs
(Mullen et al., 2011). Various cell-specific cofactors were additionally found to be
requisite for myostatin signaling in muscle cells (Kemaladewi et al., 2011). Both ALK4
and Cripto (also referred to as teratocarcinoma-derived growth factor1, Tdgf1) were
required for effective signal transduction of myostatin in myocytes, while myostatin
relied on ALK5 expression in nonmyogenic cells to signal (Kemaladew et al., 2011).
These data collectively illustrate the tremendous complexity involved in TGF-β
signaling, and the diversity of responses that may be elicited.
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As a member of this superfamily of ligands, myostatin may differentially
influence the cellular growth and differentiation of various cell types depending upon the
signaling cascade initiated, or the cofactors and the program of transcriptional activation
involved. These pathways may also be influenced differently throughout ontogeny, and
lead to a variety of physiological responses during the life history of the organism. The
array of components involved in myostatin, and TGF-β, signaling similarly provide a
platform for evolution to develop intensely divergent mechanisms and functions in
disparate physiological and cellular contexts.
MyoD and Myogenin
The architecture of teleost skeletal muscle remains unique among vertebrates,
evolved for maneuvering through a medium far denser than that encountered by
terrestrial organisms. Along the length of the body the myofibers of the skeletal muscle
are arranged in serially segmented myotomes, which are delineated by the myosepta
comprised of connective tissue (Jobling, 1994). The phenotypes of the fibers are also
distinct, with the aerobic and anaerobic fibers more acutely delineated in most teleosts
than in mammals and other vertebrates (Jobling, 1994). The anaerobic, or fast, muscle
fibers comprise the majority of the muscle mass in teleosts, positioned medially within
the body and occupying much of the myotome; while the aerobic muscle represents
comparatively little of the skeletal muscle, positioned exterior to the anaerobic muscle
immediately beneath the dermis and following the approximate contour of the lateral line
(Jobling, 1994). Within the myotomes the angle of attachment of individual anaerobic
muscle fibers ranges broadly, from fairly minimal to more severe; the collective result of
these oblique angles is to lend a somewhat helical conformation to the musculature along
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the rostral-caudal axis of the body (Jobling, 1994). By contrast, the aerobic fast fibers
display minimal heterogeneity in their angle and are arranged lengthwise along the
longitudinal axis of the body (Jobling, 1994). The skeletal muscle consists
predominantly of anaerobic fibers, with aerobic, and in some instances fibers of
intermediate phenotype and physiology, comprising relatively little of the musculature
(Jobling, 1994). The relative proportions of these fiber types, however, differ between
species, reflecting the ecological niche occupied by the fish, as well as the evolutionary
trajectories of various clades.
In many regards myogenesis in bony fish may be considered, genetically and
developmentally, indistinguishable from that in other vertebrates; indeed, it represents the
basal vertebrate condition. However, the genome duplication events experienced by the
salmonid lineages have led to functional diversification of muscle-specific paralogs
(Delalande and Rescan, 1999; Macqueen and Johnston, 2006); and teleosts exhibit
embryonic cellular migrations and patterning unique to their taxon (Stellabotte et al.,
2007; Hollway et al., 2007). As in other vertebrates, discrete regions within the
developing somites of teleosts adopt particular cell morphologies while the pluripotency
of the cells within the somitic domain simultaneously narrows (Gilbert, 2006). The
shifting morphology and gene expression of somatic locales give rise to the myoblastproducing myotome, and eventually the dermomyotome (Gilbert, 2006; Devoto et al.,
2006). These somitic derivatives produce the myoblasts which eventually form the
multinucleated syncytial muscle fibers; various regions within the myotome and
dermomyotome give rise to myoblasts which adopt more stringently defined fates and
develop into distinct fiber types (Devoto et al., 2006; Gilbert, 2006).
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Myogenesis is regulated at the level of the genome by an assembly of
transcription factors collectively designated muscle regulatory factors (MRFs), along
with the myogenic genes and cofactors (Relaix, 2006; Gilbert, 2006; Arnold and Winter,
1998). The genes and regulatory mechanisms which establish the myogenic lineage in
the embryo remain largely the same throughout ontogeny, similarly fating cells to
become myoblasts in larval (in the case of teleosts) growth and into adulthood
(Marschallinger et al., 2009; Relaix, 2006). In addition to the genes encoding the MRFs,
which include Mrf4, Myf5, MyoD, and myogenin, myogenesis is also critically dependent
upon Pax3 and Pax7, which appear to function upstream of the MRFs (Kablar et al.,
1998; Devoto et al., 2006; Arnold and Winter, 1998; Marschallinger et al., 2009; Rescan
et al., 1999; Relaix, 2006).
The process of myoblast formation, both during embryogenesis and in adult life,
exists along a continuum as stem cells and muscle precursor cells undergo proliferation
and differentiation. The MRFs are differentially expressed in accord with these cellular
processes, each functioning in different capacities to regulate progression through the cell
cycle and, in the case of mature myocytes, terminal differentiation (Chauvigné et al.,
2005; Rescan et al., 1995; Rescan et al., 1999; Hinits et al., 2009). The individual MRFs
may variously serve overlapping or complementary functions, in which several may
operate in unison to mediate a particular phase along the myogenic pathway, or mediate
processes at discrete points as the cell transitions out of the cell cycle to a differentiated
state (Chauvigné et al., 2005; Arnold and Winter, 1998). In elucidating the
developmental state of skeletal muscle the expression of MyoD and myogenin have
frequently been exploited, as these genes are widely held to be fundamentally involved in

102

the early determination, and subsequent differentiation, respectively, of myoblasts
(Steinbacher et al., 2007; Arnold and Winter, 1998).
As the myotome and dermomyotome emerge from the somite as morphologically
and functionally delineated entities the expression of Pax3 and Pax7 which originally
initiated the myogenic cascade is suppressed, replaced by an increased expression of
select MRFs, notably, Myf5, Mrf4, and MyoD; the expression of these genes is followed
soon after by that of myogenin (Relaix, 2006). The respective onset of the expression of
MyoD and myogenin, both over the course of the commitment and differentiation of
myoblasts and relative to one another, has resulted in the two genes being relegated to
distinctly different roles during myogenesis (Hinits et al., 2009; Arnold and Winter,
1998; Bergstrom and Tapscott, 2001). While MyoD is regarded as functioning in the
early stages of myocyte development by initiating myogenic determination, myogenin is
considered to mediate differentiation of the mature myocytes; though these functions may
exhibit some plasticity between vertebrate taxa (Delalande and Rescan, 1999; Hinits et
al., 2009; Arnold and Winter, 1998; Bergstrom and Tapscott, 2001). However, both
MyoD and myogenin are indispensable transcription factors throughout myogenesis, and
both belong to the closely related group of basic helix-loop-helix (bHLH) proteins
responsible for mediating skeletal muscle development (Bergstrom and Tapscott, 2001).
The precise temporal boundaries within which MyoD and myogenin function
during embryonic myogenesis and muscle growth later in ontogeny currently remain
somewhat obscure. Though they are responsible primarily for specification and
differentiation respectively, there exists the potential for overlapping or shared
functionality, which is made greater by the evolutionary differences between vertebrate
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taxa (Hinits et al., 2009; Relaix, 2006; Delalande and Rescan, 1999; Bower and Johnston,
2010a). While the purview of the two transcription factors may fluctuate between
species, and even throughout ontogeny, there exist profound structural differences
between the two proteins that dictate their abilities to mediate the processes of
specification and differentiation (Bergstrom and Tapscott, 2001). Both MyoD and
myogenin retain similar bHLH domains which are responsible for DNA binding,
however, variations in an amphipathic alpha-helix in the carboxy-termini of the two
peptides endow highly distinctive transcriptional capacities (Bergstrom and Tapscott,
2001; Arnold and Winter, 1998). The alpha-helix contained within MyoD enables the
transcription of specific myogenic genes in myoblasts, while in myogenin the alpha-helix
performs as a less discriminating gene transcription domain (Bergstrom and Tapscott,
2001). This structural difference provides a mechanistic foundation for the role of MyoD
in determination and that of myogenin in differentiation, and enables meticulous
regulation of cellular fate by means of the disparate transcriptional activities executed by
these myogenic proteins (Bergstrom and Tapscott, 2001).
The complexity of skeletal muscle development is made greater in teleosts by the
duplication of the genome, and in the case of salmonids a tetrapolidization, and the
paralogs which evolved and experience differential regulation and selection (Macqueen
and Johnston, 2006; Delalande and Rescan, 1999; Bower and Johnston, 2010a; Rescan et
al., 1994; Rescan et al., 1995; Hinits et al., 2009; Rescan et al., 1999; Chauvigné et al.,
2005). The evolution of numerous MRF paralogs allowed for specialization of function
as individual genes were subjected to distinct selective pressures and genetic variation
(Macqueen and Johnston, 2006; Bower and Johnston, 2010a; Delalande and Rescan,
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1999). Expansion of the genome permitted paralogs to adopt unique purposes, and the
presence of multiple gene copies facilitated the retention or loss of function with relative
impunity as some paralogs may operate redundantly; the preservation of a mechanism by
one enables an expansion in utility in another. In Atlantic salmon (Salmo salar) the
various MyoD paralogs are differentially regulated as myoblasts undergo proliferation
and differentiation; moreover, this differential regulation is additionally influenced by
amino acid availability and the nutritional status of the fish (Bower and Johnston, 2010a).
The paralogs have evolved to mediate different phases of myocyte development,
becoming involved in the regulation of cell populations and fate, and responding to other
physiologies such as metabolism as they are influenced by environmental variation
(Bower and Johnston, 2010a). Similarly, myogenin and multiple MyoD paralogs
experience differential expression not only as the somites develop, but within different
regions of the somites themselves (Rescan et al., 1999; Delalande and Rescan, 1999).
Further regulatory control is exerted by the promoter elements within myogenin, which
are responsible for specific functionality in the skeletal muscle (Du et al., 2003).
Successful transcriptional activation of myogenic genes by MyoD is additionally
dependent upon Pbx homeodomain proteins, embellishing epigenetic regulatory control
by ancillary factors involved in muscle development (Maves et al., 2007). Additionally,
the various MRFs are differentially regulated temporally and spatially throughout skeletal
muscle formation as the somites give rise to the myotome and dermomyotome, and cell
lineages are increasingly restricted (Chauvigné et al., 2005; Bower and Johnston, 2010a;
Hinits et al., 2009; Rescan et al., 1999). Consistent with the roles of MyoD and
myogenin in specification and differentiation, respectively, myogenin expression was
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observed subsequent to that of MyoD paralogs in rainbow trout (Oncorhynchus mykiss)
(Delalande and Rescan, 1999).
Among the defining morphological features of teleost skeletal musculature is the
spatial delimitation of the fiber types, which is instructed by the differential expression of
the MRF genes, as well as cell migration and cytokine signaling in the embryo and adult
tissue (Henry and Amacher, 2004; Hirsinger et al., 2004; Devoto et al., 1996; Rescan et
al., 1995; Hinits et al., 2009; Rescan et al., 1999). The development of fast muscle fibers
in zebrafish (Danio rerio) relies upon the prior formation of slow fibers and the hedgehog
signaling which directs it (Henry and Amacher, 2004). The medio-lateral movement
through the somite of muscle cells with a slow phenotype acts in a permissive fashion,
enabling fast muscle fibers to differentiate in a trailing fashion (Henry and Amacher,
2004). The relative positions of cells within the somite similarly influence the fiber
phenotype as cell migration in the myotome and dermomyotome leads to the
development of fiber types from cells which have taken up residence in the various
regions of these embryonic structures (Stellabotte et al., 2007). Indeed, aggregations of
cells were discovered in zebrafish which were defined by gene expression characteristic
of different fiber types even before the formation of somites (Devoto et al., 1996).
The wholesale migration of populations of cells, and reconfiguration of somites,
are integral not merely for embryonic and early life stages, but for providing a foundation
for growth potential in later life as well (Marschallinger et al., 2009; Steinbacher et al.,
2007; Hollway et al., 2007; Stellabotte et al., 2007). Post-embryonic muscle growth in
fish occurs through both hypertrophy and hyperplasia of the muscle, hyperplastic growth
occurring in mosaic and stratified morphologies within the myotomes (Mommsen, 2001;
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Johnston et al., 2010). Stratified hyperplasia takes place as the distal regions of the
dermomyotome deposit new layers of cells in the trunk musculature as they move
laterally from the notochord; while mosaic hyperplasia creates a heterogeneous landscape
of muscle fibers as satellite cells scattered throughout the myotome differentiate into new
myocytes, or are incorporated into existing myofibers as they grow in size (Johnston et
al., 2010).
Hyperplastic growth in post-embryonic stages necessitates populations of satellite
cells which are competent to continue proliferating, furnishing daughter cells for new
myofibers as well as maintenance of their own populations (Johnston et al., 2003;
Johnston et al., 2010). Dermomyotome-derived myogenic precursor cells distinguished
by the expression of Pax7 appear to function as precursor cells available for hyperplastic
growth of fast muscle fibers later in ontogeny (Marschallinger et al., 2009); while
hyperplasia of slow muscle fibers may occur by means of different mechanisms at
various points in development (Barresi et al., 2001). In more derived vertebrates various
mechanisms for securing populations of satellite cells for continued growth have been
proposed (Gros et al., 2005; Schultz, 1996), while in zebrafish a dramatic reorganization
of the somite has been demonstrated to give rise to a novel population of muscle
progenitor cells (Hollway et al., 2007). For species exhibiting indeterminate growth,
such as salmonids, the inherent value of populations of cells which are capable of
continuous proliferation commensurate with the demands imposed by continuous
hyperplasia is apparent. The addition of skeletal muscle mass through an increase in
fiber numbers demands that satellite cells constitutively produce new cells while
simultaneously preserving a population of stem cells which is not exhausted.
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The physiology and regulation of myogenesis in salmonids is rendered more
complex due to the genome tetraploidization that generated paralogs of many of the
MRFs involved in muscle development. The evolution of these paralogs permitted more
specialized and highly regulated mechanisms for muscle development to emerge. This in
turn led to an expansion of the potential functions which might be fulfilled by these genes
as it made possible the potential for them to take on novel functions or regulatory control.
This would have been essential for a group such as the salmonids, which inhabit diverse
environments and exhibit substantial growth potential. It also made possible the
heterochronic manipulation of the various paralogs, which would have had implications
for the radiation of genera and species, and modes of growth. The potential for the
evolution of redundant and novel functions alike within myognenic genes was enhanced
by increasing the genetic framework in which selection could operate, simultaneously
providing a means by which to elaborate regulation of muscle development.
Additionally, an indeterminate mode of growth makes possible a broader range of
functions for the MRFs throughout ontogeny. Genes that serve in a particular capacity at
a discrete point in development may execute similar or highly unique functions at a later
point, a potential which represents distinctive opportunities in continuously growing
species such as salmonids.
Growth hormone/IGF
Somatic growth, as with any prevailing physiological process, is profoundly
complex and extensively regulated. It must be integrated with the multitude of other
physiologies occurring simultaneously, and in such a way that it proceeds optimally
while at the same time not detracting from other, sometimes competing, processes.
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Additionally, growth is assimilated with an organism’s environment, and the functioning
of metabolic paradigms such as heterothermy and homothermy are differentially
impacted by the extrinsic surroundings. Growth may be considered to occur from the
point of the initial division of the fertilized egg, and as such, is imbued with tremendous
complexity as growth physiology changes continuously throughout ontogeny. While in
many organisms sexual maturity heralds the conclusion of somatic growth, other species
grow indeterminately and continuously throughout their lifetime. Moreover, cell and
tissue replacement occurs in all organisms at all points in ontogeny. The physiology of
growth adopts a novel and utterly divergent significance in the context of deregulation
and disease. Unrestrained growth is the hallmark of tumorigenesis and metastasis,
wherein cells, often cancerous, may proliferate unchecked.
While growth may be considered to be directed by a staggering array of ligands
and ancillary molecules, somatotropin (growth hormone, GH), insulin, and the insulinlike growth factors I and II (IGF-I and IGF-II) may be regarded as the fundamental
molecular effectors of somatic growth, which encompasses myogenesis (Hadley and
Levine, 2007; Florini et al., 1996; Wood et al., 2005; Duan, 1997). The somatotropic
axis is principally comprised of the hypothalamus, the hypophysis, and the liver, along
with associated ligands including, but not limited to, growth hormone-releasing hormone
(GHRH), somatostatin, somatotropin, IGF-I and –II, and insulin-like growth factor
binding proteins (IGFBPs), as well as receptors, which have been found throughout
vertebrate clades, including in teleosts (Florini et al., 1996; Moriyama et al., 2000;
Björnsson, 1997). Historically, somatic growth was considered to be mediated
exclusively by hepatically derived IGFs, the release of which was stimulated by growth
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hormone originating in the hypophysis, though more recent evidence has inspired a
reevaluation of this canonical view (LeRoith et al., 2001; Yakar et al., 1999; Sjögren et
al., 1999).
The functioning and activities of the ligands within the somatotropic axis are
acutely dependent upon, and responsive to, not only the internal physiology but also the
environment and a number of abiotic factors (Johnston et al., 2003; Johnston, 2006;
Björnsson, 1997). Teleosts, as heterothermic vertebrates, are profoundly impacted by
temperature, which influences growth throughout ontogeny (Gabillard et al., 2003;
Johnston et al., 2011; Johnston, 2003). Growth and metabolic activities are swayed by
ambient temperature, photoperiod, nutrient availability and feeding, as well as oxygen
concentrations, all of which have been discovered to dramatically impact growth
physiology and the expression profiles of growth related genes in teleosts (Johnston et al.,
2003; Taranger et al., 2006; Chauvigné et al., 2003; Oakes et al., 2007; Johnston, 2006;
Ren et al., 2010). Environmental cues such as photoperiod are received by the central
nervous system and translated into the release of somatotropin, and have been
demonstrated to elicit alterations in growth, and myogenesis specifically, and sexual
maturity; thus illustrating the malleability of the phenotypic response and its
susceptibility to extrinsic stimuli (Johnston et al., 2003; Taranger et al., 2006). Similarly,
the availability of food resources and the nutritional status of an organism fluctuates
continuously, which influences growth and metabolism on a temporal continuum, ranging
from hourly to seasonal to annual cycles (Erbay et al., 2003; Oakes et al., 2007, Bower et
al., 2008; Wood et al., 2005). In an experimental context the expression profiles of
genes in the somatotropic axis have been observed to differ intensely as fish were fasted
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and subsequently fed to satiation (Bower et al., 2008; Chauvigné et al., 2003; Montserrat
et al., 2006), and similar transcriptional control can be envisioned as feeding
opportunities in wild fish populations are subject to prey availability.
Postnatal growth in vertebrates relies on the functionality of growth hormone and
the suite of cellular processes it mediates; the central function of this endocrine factor is
evidenced by its emergence early in vertebrate evolution ( Kawauchi and Sower, 2006;
Hadley and Levine, 2007). Growth hormone operates in concert with, as well as
independently of, other effectors within the somatotropic axis, participating in
carbohydrate, lipid, and protein metabolism along with a host of other cellular workings
(Wang et al., 2004; Florini et al., 1996; LeRoith et al., 2001; Lindén et al., 2000). The
preponderance of information regarding the mechanisms of action and regulation of
growth hormone have been derived from research carried out in mammalian species;
while structural and/or functional homology cannot explicitly be inferred for fish,
specifically teleosts, a number of the principal components and mechanisms are common
to both (Kawauchi and Sower, 2006; Johnston et al., 2011; Björnsson et al., 2002 ) and
the similarities and differences will only be better resolved as new research brings further
insight. Growth hormone is synthesized in, and secreted from, the somatotrophs of the
adenohypophysis, the stimulus and suppression of its release mediated in part by growth
hormone-releasing hormone and somatostain, respectively, from the hypothalamus (Klein
and Sheridan, 2008; Hadley and Levine, 2007). Additionally, gastric and intestinal
ghrelin have been found to stimulate growth hormone release in mammals and teleosts
alike (Wang et al., 2002; Hadley and Levine, 2007). Growth hormone binding of the
growth hormone receptor initiates intracellular signaling cascades responsible for the

111

regulation of downstream genes in the somatotropic axis and other metabolic pathways
(Herrington et al., 2000; LeRoith et al., 2001; Herrington and Carter-Su, 2001).
Sharing a degree of amino acid sequence homology with related receptors, the
growth hormone receptor belongs to the cytokine/hematopoieten superfamily of receptors
(Herrington and Carter-Su, 2001). The growth hormone receptor contains a single
extracellular domain as well as sole transmembrane and cytoplasmic domains, and while
homology of the receptor within vertebrate clades is relatively low, the extracellular
domain remains an exception, exhibiting substantial homology (Björnsson et al., 2002;
Argetsinger and Carter-Su, 1996). The extracellular domains of the mammalian
receptors thus far characterized contain seven cysteine residues, six of which are
associated through disulfide bonds; salmonid receptors, however, possess only four of
these cysteines (Björnsson et al., 2002; Argetsinger and Carter-Su, 1996). A single
domain of the growth hormone ligand initially binds to the extracellular domain of a
single growth hormone receptor, followed sequentially by the recruitment and binding of
a second receptor to a domain on the ligand distinct from the one which bound the initial
receptor (Cunningham et al., 1991).
While it remains uncertain if this binding induces a conformational change in the
receptor-ligand complex, growth hormone binding does solicit association of intracellular
Janus kinase 2 (JAK2) peptides with the intracellular domains of the dimerized receptors
at a conserved region dominated by prolines in close proximity to the membrane, termed
Box 1 (Herrington and Carter-Su, 2001). The bound JAK2 proteins reciprocally
phosphorylate one another on discrete activating tyrosine residues, and subsequently
phosphorylate themselves as well as the growth hormone receptor, thereby creating an
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active binding site for intracellular signaling molecules (Herrington and Carter-Su, 2001).
Certain of the signal transducer and activator of transcription (STAT) proteins are among
those known to bind the activated growth hormone receptor complex, and do so through
their SH2 (Src (sarcoma) Homology 2) domains (Argetsinger and Carter-Su, 1996). The
STATs activated by the growth hormone receptor cascade subsequently complex with
one another and translocate to the nucleus, regulating transcription of downstream genes
(Ihle, 1996). In addition to transducing signals through STAT proteins, growth hormone
binding of its receptor initiates mitogen activated protein kinases (MAPKs) such as
extracellular signal regulated kinases (ERK)-1 and -2 (Argetsinger and Carter-Su, 1996).
The insulin receptor substrates (IRS)-1 and -2 are also mediated by growth hormone
receptor activation, which, through SH2 binding of phosphoinositide 3-kinase (PI3K),
lead to metabolic regulation of lipogenesis and most likely glucose transport by PI3K
(Argetsinger and Carter-Su, 1996). While the array of tyrosine residues in the
intracellular domain of the salmonid receptor has been found to differ from that of other
vertebrates (Björnsson et al., 2002) the JAK-STAT signaling cascade initiated by growth
hormone appears present in teleosts (Lee et al., 2001). Entrenched in a multitude of
signaling pathways and anabolic mechanisms, growth hormone is an integral and
dynamic component of growth physiology. However, along with these many functions is
the endocrine regulation of, and interaction with, the insulin-like growth factors.
Equally, and in some contexts perhaps more, imperative to growth in vertebrates
are the insulin-like growth factors-I and –II (IGF-I and IGF-II), their associated receptors,
binding proteins, and coordinate molecules such as the acid-labile subunit (ALS) (Wood
et al., 2005; Björnsson et al., 2002; Sjögren et al., 1999). The vertebrate IGFs are fairly
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well conserved structurally and the mammalian ligands resemble immature insulin,
containing four unique domains, B, C, A, and D (Duan et al., 2010). The IGFs are
initially synthesized in a prohormone conformation, containing a hydrophobic signaling
domain that mediates secretion, which is subsequently cleaved but leaves the hormones
in an immature form as an E domain remains (Wood et al., 2005). The mature forms of
the IGFs emerge as this E domain is proteolytically cleaved (Moriyama et al., 2000).
The IGFs are bound by two distinct receptor types, IGF-I receptors (IGF-1R) and
IGF-II receptors (IGF-2R), which execute both confluent and unique signaling
mechanisms in fish and mammals alike (Duan et al., 2010; Wood et al., 2005). The IGF1R is cleaved following initial translation as a single peptide into distinct α and β subunits
of approximately similar sizes, which are then bound to one another through disulfide
bonds, forming an αβ hemireceptor (Wood et al., 2005). This partial receptor
subsequently associates with another identical hemireceptor, giving rise to the functional
α2β2 holoreceptor (Butler et al., 1998). Ligands, primarily IGF-I, are bound by the
extracellular α domain, while the cytosolic β domain carries out phosphorylation as the
tyrosine kinase domain, and defining the IGF-1R as a member of the tyrosine kinase
family of transmembrane receptors (Florini et al., 1996; Wood et al., 2005). A
conformational change in the IGF-1R brought about by ligand binding is translated into
activation of the β domain through autophosphorylation of discrete tyrosine residues
(Butler et al., 1998; Florini et al., 1996).
Activation of the β domain initiates several distinct signaling cascades as multiple
intracellular effectors are drawn in to the active site of the cytoplasmic IGF-1R domain
(Wood et al., 2005). The insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) are the
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preeminent signaling factors recruited to the β domain, and the IGF-1R is somewhat
unique among the tyrosine kinase receptors in that IRS-1 and IRS-2 are utilized as
intermediaries between the activated IGF-1R and several secondary intracellular
substrates involved in different pathways (Butler et al., 1998). Deficiencies in IRS
function prove catastrophic to the coordination and perpetuation of downstream signaling
in muscle tissue (Long et al., 2011). Intracellular messenger proteins containing SH2
domains are among those enlisted by the IGF-1R to communicate IGF-I binding to the
Ras/MAPK pathway; IGF-I binding additionally initiates PI3K and Akt/mammalian
target of rapamycin (Akt/mTor) pathways through IGF-1R mechanisms (Duan et al.,
2010; Wood et al., 2005).
These cascades, while commonly initiated by IRSs, and ultimately IGF-I, are
variously involved in processes such as metabolism and nutrient utilization, and
transcriptional activation related to growth (Florini et al., 1996; Butler et al., 1998).
IGF-I signaling promotes somatogenesis by regulating contrary metabolic processes
simultaneously, stimulating anabolic pathways while antagonizing the expression of
genes involved in protein degradation (Cleveland and Weber, 2009; Seiliez et al., 2010;
Stitt et al., 2004). Transcription of the muscle RING-finger proteins (MuRFs), which are
involved in ubiquitination and degradation of muscle protein, is carried out by FOXO
(Forkhead box) transcription factors (Witt et al., 2005; Stitt et al., 2004). IGF-I
antagonizes FOXO nuclear translocation and transcriptional activation of MuRFs,
thereby preventing breakdown of muscle tissue by ubiquitin ligases (Stitt et al., 2004;
Seiliez et al., 2010). The PI3K and Akt pathways which are recruited for anabolic
metabolism are similarly enlisted in down-regulating these ubiquitin ligases through
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interference with the actions of FOXO effectors, operating in teleosts and mammals alike
(Cleveland and Weber, 2009; Stitt et al., 2004; Seiliez et al., 2010).
In contrast to the varied responses mediated by the IGF-1R the type II IGF
receptor has, at present, not been found to serve in any signaling pathway; indeed, the
IGF-2R appears to be without any catalytic motif or capacities, though is requisite for
survival (Duan et al., 2010; Wood et al., 2005). While the affinity of the mammalian
IGF-2R for IGF-II tremendously exceeds that for IGF-I, binding of IGF-II initiates
endocytosis and degradation of the receptor-ligand complex rather than signal
transduction (Duan et al., 2010). The IGF-2R has, however, has been established in
mammals as being identical to a mannose 6-phosphate (M6P) receptor (Duan et al.,
2010). While the IGF ligands and receptors have been perhaps most extensively studied
in mammals their structures and/or physiological functions have remained reasonably
conserved with those in teleosts (Pozios et al., 2001; Duan et al., 1997; Wood et al., 2005;
Moriyama et al., 2000).
The IGF-1R has been described in a number of teleost species, including rainbow
trout (Greene and Chen, 1999), and as the IGF-1R signaling pathways are elucidated in
teleost species it is becoming clear that they are homologous with those of mammals
(Pozios et al., 2001; Wood et al., 2005); notably, a β domain tyrosine kinase has been
found to be present in rainbow trout (Greene and Chen, 1999). Unlike mammals, the
zebrafish IGF-1R bound both IGF-I and IGF-II in a comparable manner (Pozios et al.,
2001). An IGF-2R with binding specificity for the IGF-II ligand has been found in
brown trout (Salmo trutta) (Mendez et al., 2001), however, this work was performed with
embryos rather than fish at later ontogenetic stages. IGF-II signaling fulfills functions
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unrelated to metabolism in zebrafish during embryonic development (White et al., 2009),
suggesting differential roles at various points during the life history of the species. While
the structures and pathways of the IGF system have exhibited conservation across
vertebrate taxa the numerous commonalities do not explicitly imply universal homology
in every aspect of expression, function, or mechanism of IGF-mediated growth (Wood et
al., 2005).
The somatotropic axis and its attendant components are accountable to stringent
regulation at myriad points both as a function of the physiology of the organism, and
along a temporal continuum. Growth hormone, IGFs, receptors, and stimulatory factors,
both positive and negative, operate within the somatotropic axis at multiple levels of
organization throughout ontogeny. Growth hormone and the IGFs are strictly moderated
by feedback mechanisms as are all endocrine effectors. Excitatory and inhibitory stimuli
originating in the external environment or internal physiology regulate the production of
factors which alternately promote or antagonize the release of growth factors.
Somatostatin ceases growth hormone release (Klein and Sheridan, 2008), in addition to
exerting control over hepatic IGF-I expression (Very et al., 2008), while growth
hormone-releasing hormone stimulates ligand production and excretion. The tissues
responsible for these effectors incorporate signals pertaining to the nutritional status,
environmental conditions, and developmental stage of the organism and respond
accordingly. Growth hormone in turn functions to mediate its anabolic activities both
directly and indirectly (Wang et al., 2004), thereby simultaneously serving as a regulator
of IGFs as well as itself as feedback to the adenohypophysis and hypothalamus promotes
or halts further synthesis. The mechanisms relating information about the concentration
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of hormones present in the organism may all be considered to operate through cyclical
feedback, though they may occur on spatial scales varying in scope. Paracrine and
autocrine regulation of growth factors contributes to the command of growth factors, and
in some contexts may prove to supersede endocrine actions (Yakar et al., 1999).
The distribution and regulation of growth hormone and IGF receptors has proven
to be another mechanism operating in concert with the endocrine regulation of these
ligands to dictate the response of cells and tissue to various growth stimuli; the liver
contains abundant growth hormone receptors though many other tissues contain the
receptor as well (Flores-Morales et al., 2006; Wood et al., 2005). Muscle-specific
cofactors are requisite for the maintenance and turnover of IGF receptors (Demonbreun et
al., 2010) while intracellular protein interactions provide a mechanistic basis for
moderating growth hormone signaling pathways (Flores-Morales et al., 2006). Growth
hormone signaling, like that of myostatin and innumerable other ligands, is governed by
receptor expression, turnover, and degradation (Flores-Morales et al., 2006). Signaling
through the growth hormone receptor is dependent in large part on the suppressors of
cytokine signaling (SOCS), a group of related proteins some of which act specifically on
the JAK-STAT pathway impelled by growth hormone binding, promoting ubiquitination
and degradation of the JAK and STAT proteins involved in signal transduction (FloresMorales et al., 2006).
Paramount to the endocrine and paracrine actions of IGFs are the insulin-like
growth factor binding proteins (IGFBPs), with at least six distinct peptides currently
characterized in mammals (Duan, 1997). These proteins are characterized by the
presence of shared motifs and outstanding affinities for IGF-I and IGF-II, though remain
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unique with respect to certain of their structural and functional attributes (Duan and Xu,
2005; Clemmons, 2001). The IGFBPs serve in a variety of capacities, including
safeguarding circulating IGFs from proteolytic cleavage or degradation and thereby
extending their viability (Duan et al., 2010; Wood et al., 2005). Additionally, they appear
to participate in making the IGFs available to tissues in a spatially discrete fashion by
sequestering them in localized regions through binding them within complexes from
which they can be released, as well as negotiating their movement from the circulation to
the receptors on the cell surface (Duan, 2002). While the multiple IGFBPs fulfill diverse
physiological necessities a complex incorporating IGFBP-3 and a glycoprotein, the acidlabile subunit (ALS) figure prominently in the regulation of mammalian IGFs and their
somatic transport (Wood et al., 2005). These IGFBP interactions evidence mechanisms
resembling paracrine and autocrine control of ligand availability and may represent a
means of satisfying the varying requirements of different tissues for these growth factors
(Duan, 2002).
As a remarkably dynamic and highly involved process somatic growth necessarily
represents the culmination of the interaction of a host of molecules. Figuring
prominently in this physiology, the IGFs and growth hormone have consistently been the
focal points on which elucidating growth processes has centered. However, the precise
nature of their interaction, and the manner in which each functions dependently or
independently to mediate growth, remains the subject of some debate. Initially, the
model proposed installed hypophysial growth hormone as the consummate mediator of
growth and anabolic metabolism as it stimulated the hepatic synthesis and release of the
IGFs, which subsequently functioned as the ultimate growth promoting factors
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(Schlechter et al., 1986; Butler and LeRoith, 2001; LeRoith et al., 2001). Growth
hormone was interpreted to operate through the hepatically-derived IGFs, rather than
directly, to stimulate growth and early investigations demonstrating direct growth
hormone actions overlooked the tissue specific capacity for initiating IGF actions
(Isaksson et al., 1982; LeRoith et al., 2001). As these hormones became better
understood and their discrete regulation and expression were better resolved the paradigm
shifted, recasting growth hormone and the IGFs in both independent and dependent roles
(LeRoith et al., 2001; Wang et al., 2004; Lupu et al., 2001). IGF expression was found to
be all but ubiquitous, no longer held as exclusively the purview of hepatocytes,
suggesting that tissue-specific autocrine and paracrine IGF actions had a previously
unrealized significance (Björnsson et al., 2002; Yakar et al., 1999; Sjögren et al., 1999).
While IGFs derived from the liver remain indispensable to a suite of physiological
processes it was found that mammalian chondrogenesis was equally, if not more so,
dependent upon locally derived IGFs (Ohlsson et al., 2009). The tissue specific
expression of IGFs has exhibited the ability to rescue a normal growth phenotype in the
absence of hepatically-derived IGFs, and indicated that paracrine and autocrine IGF
actions, whether induced by growth hormone or independent of it, are fundamental to
somatogenesis (Yakar et al., 1999; Sjögren et al., 1999; Tanaka et al., 1996).
In addition to the novel mechanisms by which the IGFs functioned in somatic
tissues, independent actions for growth hormone which did not rely on the IGFs were
also realized (Wang et al., 2004; Lupu et al., 2001). Definitive confirmation of the direct
action of growth hormone on mammalian chondrogenesis could be seen in the growth
deficiencies exhibited by double mutant Ghr/Igf-I-null mice, which were more severe
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than those found in mice containing only a single mutation (Lupu et al., 2001). Similarly,
IGF-I-null mice were found to have compromised hypertrophy of chondrocytes, while
Ghr-null mice exhibited deregulation of cell proliferation and cell growth (Wang et al.,
2004). These data collectively demonstrate autonomous roles for growth hormone in
mediating growth, as well as pointing to the substantial redundancy and overlap which
exists in the functioning of the IGFs and growth hormone (Lupu et al., 2001; Wang et al.,
2004).
The improved understanding of these cardinal growth factors has revealed some
of the mechanisms which underpin their stimulation of growth. Growth hormone and the
IGFs were originally regarded as independently responsible for the disparate cellular
process of proliferation and differentiation (LeRoith et al., 2001). Subsequently, this
clear delineation for each in the regulation of cellular events has become blurred as it has
been revealed that growth hormone and the IGFs participate in both proliferation and
differentiation in varying capacities depending upon the context in which they are
operating (Ren et al., 2010; LeRoith et al., 2001; Rosenthal and Cheng, 1995; Engert et
al., 1996). The failure of both hypertrophic and hyperplastic growth in Ghr-null mice
supports a role for growth hormone in both cell proliferation and differentiation (Wang et
al., 2004). Additionally, IGFs are capable of alternately promoting differentiation or
proliferation in myoblasts depending upon the oxygen concentration available to the cells
and the signaling pathways enlisted (Ren et al., 2010; Coolican et al., 1997). The
disparity in cell fates under normoxic and hypoxic conditions is mediated by the
differential control of the numerous signaling pathways initiated by IGF binding; hypoxia
leading to proliferation through activation of specific pathways while normoxia slates
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cells for differentiation by means of alternative cascades (Ren et al., 2010; Duan et al.,
2010). In this way identical ligands are able to execute two otherwise conflicting cellular
processes (Ren et al., 2010). Growth hormone and the IGFs may now be considered to
function both independently and in concert to regulate somatogenesis; the vastly
expanded role for local IGF actions reveals that there is likely tremendous opportunity for
spatially distinct regulation, facilitating more refined control of growth (Ohlsson et al.,
2009; LeRoith et al., 2001).
The somatotropic axis of teleosts differs minimally from that of other vertebrates
with respect to major components such as the organs and endocrine factors involved, and
some of the signaling pathways utilized (Wood et al., 2005). Growth physiology in
teleosts has been intensively studied not only in an effort to understand the diversity and
homology of these processes across vertebrate species, but because it represents a means
of enhancing species valuable to the commercial industry (De-Santis and Jerry, 2007;
Garber et al., 1995). With the advent of commercial aquaculture artificial selection has
enhanced some of the components within the somatotropic axis known to be essential to
growth regulation (Tymchuk et al., 2009; Neregård et al., 2008).
Growth hormone has been utilized to enhance somatic growth in teleosts, most
often salmonids and other commercially valuable species, through both the generation of
transgenic organisms and the introduction of exogenous hormone (Garber et al., 1995;
Levesque et al., 2008; Devlin et al., 2009; Devlin et al., 2004). The genetic and extrinsic
manipulations of the somatotropic axis have both resulted in similar alterations in gene
expression, increasing anabolic pathways such as those involving IGF-I and myogenic
factors, demonstrating at least minimal conservation of some of the fundamental
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components of the vertebrate growth program (Biga et al., 2005; Levesque et al., 2008;
Devlin et al., 2009; Biga et al., 2004a). As heterothermic vertebrates the metabolic
demands of teleosts differ from those of mammals and other homeotherms, which
potentially influences the somatotropic axis in fish in unique ways. The expression
profiles of genes within the somatotropic axis in fish have been directly correlated to the
nutritional status of the animal (Chauvigné et al., 2003; Amaral and Johnston, 2011;
Oakes et al., 2007; Montserrat et al., 2006; Bower et al., 2008; Bower and Johnston,
2010b; Campos et al., 2009).
Nutrient deprivation and surfeit result in the differential regulation of the IGFs
and their receptors (Erbay et al., 2003; Montserrat et al., 2006; Chauvigné et al., 2003), as
well as those in the catabolic and degradation pathways (Amaral and Johnston, 2011).
The two IGFs responded to nutrient availability with dramatically different expression,
IGF-I typically exhibiting more dramatic variations in expression than IGF-II (Chauvigné
et al., 2003; Montserrat et al., 2006). These findings suggest disparate functions for these
growth factors in the response to nutrient flux and the regulation of anabolic and
catabolic pathways; amino acid availability directly influencing the IGF-I response as
muscle mass was augmented in Atlantic salmon (Salmo salar) (Bower and Johnston,
2010b). Moreover, the enhancement in growth brought about by growth hormone
transgenesis or the administration of an exogenous peptide was the direct result of
improvements in the utilization of nutrients and a metabolic shift towards muscle
accretion and protein synthesis rather than lipid deposition (Garber et al., 1995; Oakes et
al., 2007). This indicates that alterations to the somatotropic axis yield a mechanism by
which resources may be used more efficiently rather than simply requiring greater

123

volumes of them. This may be the product of refinements to anabolic pathways in the
context of modified expression of somatogenic genes, or the result of some as yet
undiscovered cellular mechanism that may improve growth physiology within discrete
contexts.
Interestingly, some of the ligands foremost involved in myogenesis and growth
physiology, myostatin and those of the growth hormone-IGF (GH-IGF) axis, have
demonstrated manifest interactions and complementary gene expression (Liu et al., 2003;
Roberts et al., 2004; Oldham et al., 2009; Biga et al., 2004b). Myostatin, a negative
regulator of skeletal muscle in mammals and the GH-IGF axis serve diametrically
opposing metabolic functions, perhaps accounting for the nature of the interaction
between the two, which is characterized by a mitigating effect of growth hormone on
myostatin expression and concentrations of the mature myostatin protein (Liu et al., 2003;
Biga et al., 2004b; Oldham et al., 2009). Growth hormone administration in humans
produced a significant decrease in myostatin expression, while in vitro exposure of
myocytes to the peptide produced similarly significant reductions in expression (Liu et
al., 2003). Moreover, as growth hormone receptor expression was experimentally
inhibited (Liu et al., 2003), or declined with age (Marcell et al., 2001) a corresponding
increase in myostatin expression was observed. In mammals, the pathways recruited by
growth hormone to antagonize production of the mature myostatin protein differed from
those involved in regulating expression of the gene, suggesting differential transcriptional
and post-translational control (Oldham et al., 2009). Similar, although inverse,
relationships have been found at other points along the GH-IGF axis as TGF-β1 has been
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found to interfere with the expression of IGF-II and synthesis of the protein, as well as
IGF-I signaling, within muscle (Gardner et al., 2011).
Interactions between myostatin and the GH-IGF axis identical to those in
mammals have also been described in teleosts (Roberts et al., 2004; Biga et al., 2004b).
Increased growth hormone expression in transgenic coho salmon (Oncorhynchus kisutch)
yielded reductions both in myostatin expression and the mature protein (Roberts et al.,
2004). Supporting a direct interaction between the myostatin gene and growth hormone
peptide is the presence of a sequence in the regulatory domain of both myostatin genes in
brook trout (Salvelinus fontinalis) that is responsive to growth hormone (Roberts and
Goetz, 2003). Moreover, the expression of the two myostatin genes in both oxidative and
glycolytic muscle of salmonids was differentially regulated in the case of increased
growth hormone levels, whether achieved through endogenous or exogenous means
(Biga et al., 2004b; Roberts et al., 2004). These data indicate not only that the two genes
function in disparate capacities in the regulation of myogenesis, but that their response to
the GH-IGF axis is similarly unique (Roberts et al., 2004; Biga et al., 2004b). While the
antagonism of myostatin protein and mRNA by growth hormone suggests that myostatin
functions to inhibit myogenesis in teleosts as it does in mammals, and hyperplasia
accompanies reduced myostatin expression coincident with growth hormone increases
(Roberts et al., 2004; Biga et al., 2004b), there remains the possibility that the impact of
the GH-IGF axis on myostatin is ancillary to other anabolic effects of growth hormone
augmentation which remain dominant. The potential for interactions between these
molecules at the transcriptional or translational levels remains intriguing as they may
further understanding of the evolution of growth physiology in vertebrates.
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Aquaculture
With a burgeoning global population continuing to increase with each passing
year, ever more strain is being placed on finite and dwindling resources. Increasingly,
the aquaculture industry and its attendant technologies are being looked to for viable
solutions to the perpetually growing food demands imposed by expanding human
consumption. Changing demographics and upward economic mobility have already
substantially heightened demand for a variety of aquaculture products in many parts of
the world (Gjedrem et al., 2012). The relative nature of many of these products as luxury
items in many societies contrasts sharply with their role in poverty-stricken nations where
they are relied upon in a subsistence context (Ewoukem et al., 2012; Gjedrem et al.,
2012). Tragically, but perhaps not surprisingly, those in greatest need of stable and
successful aquaculture infrastructure are the same who are most severely disadvantaged
by disruptions to whatever framework may be in place in the event of natural disasters or
similar occurrences (Rethinking Poverty, 2010). The escalating necessity and desire for
aquaculture products worldwide is certain only to fuel expansion and elaboration of an
industry already developing at an accelerated pace.
Commercial scale aquaculture embodies one of the more contemporary methods
of food production for human consumption (Subasinghe et al., 2009), and as a fledgling
industry is in the midst of refining and honing the technologies and practices which will
almost certainly secure its place as the preeminent means of obtaining fish protein in the
coming decades. Presently, cultured fish comprises more than one quarter of the fish
brought to market (Naylor et al., 2000), a figure which is certain to swell alongside
growing populations. However, expansion of the industry has been plagued by a number
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of obstacles which must be resolved if the viability and profitability of aquaculture are to
be cultivated.
Foremost among these challenges is the procurement of adequate supplies of feed,
in particular for cultured species that rely primarily on fish protein (Naylor et al., 2000;
Pelletier et al., 2009). While the greatest volumes of fish oil and fish meal are consumed
in the production of poultry and pork protein, the aquaculture industry demands
substantial amounts of the same for use in bringing finfish to market (Naylor et al., 2000;
Péron et al., 2010; Pelletier et al. 2009). Supplying adequate feed represents one of, if
not the, single greatest expenses in the operation of aquaculture facilities (Naylor et al.,
2000). The fact that herbivorous and omnivorous species rely more heavily on plantderived proteins than those from fish sources (Naylor et al., 2000) may, in coming years,
lead to a reconsideration of aquaculture practices wherein such species are preferentially
grown in favor of piscivorous fishes.
The tremendous cost and energies associated with securing fish meal and fish oil,
as well as the dependence on fisheries targeting lower trophic level species, has
encouraged considerable investigation into alternative sources of raw materials for feed
production (Pelletier and Tyedmers, 2007; Pelletier et al., 2009; Naylor et al., 2000).
While the metabolic physiology of teleosts enables them to conserve greater amounts of
the protein taken in when compared to livestock species (Pelletier et al., 2009; Gjedrem et
al., 2012) the sheer magnitude of aquaculture production, along with dwindling stocks of
wild fisheries, preclude anything less than the most aggressive pursuit of alternative feed
sources (Pelletier et al., 2009; Naylor et al., 2000; Péron et al., 2010).
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A variety of alternatives to protein derived from fish sources have been
investigated, including the remnants and discards from the processing of livestock such
as bone and blood meal (Naylor et al., 2000). Plant protein sources, principally soy, corn,
and canola oils, have come to the fore as prospective substitutions for fish meal and fish
oil (Enterria et al., 2011; Collins et al., 2012). As sustainable practices are being realized
as a mainstay for the aquaculture industry the origination of feed sources, traditional and
alternative alike, and the environmental impacts of the individual constituents are being
more severely scrutinized. Associated with each of the components of all types of feed
are both the financial and environmental costs of procurement, processing, refinement,
and transportation (Péron et al., 2010; Pelletier and Tyedmers, 2007; Pelletier et al. 2009;
Subasinghe et al., 2009). Indeed, the environmental detriments wrought by current
mechanisms of feed production are so cumbersome and disproportionately great as to
obliterate any gains made by the use of organically derived materials (Pelletier and
Tyedmers, 2007).
At the intersection of increased demand and the necessity to fulfill it in
sustainable fashion lies the opportunity to seize upon classical, as well as more
contemporary, techniques to advance both of these ends with singular efficacy. The
installation and development of selective breeding programs has been championed as a
means of enhancing the growth rates of species central to aquaculture (Gjedrem et al.,
2012). Capitalizing on traits inherited in Mendelian fashion, aquaculturists have the
means to improve broodstock and overall yield as the most desirable alleles and
characteristics are identified and selected for (Gjedrem et al., 2012). Similarly,
transgenic means hold vast potential to expedite this process and develop organisms
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which are not only able to reach market size more rapidly, but do so with greater
efficiency. A variety of genomic techniques have long been employed in aquaculture, as
well as other contexts (Horváth and Obrán, 1995), while more recently transgenesis has
demonstrably improved growth and metabolic physiology in salmonids (Oakes et al.,
2007).
Presently, the AquAdvantage® salmon, produced by AquaBounty Technologies®,
is vying to become the first transgenic animal product approved in the United States for
human consumption. This fish, which experiences enhanced growth due to a
constitutively expressed Chinook salmon (Oncorhynchus tshawytscha) growth hormone
gene which is under the control of an ocean pout (Zoarces americanus) promoter is able
to be harvested in substantially less time than other salmon (www.aquabounty.com).
Despite the need for such innovative technologies, approval from the United States Food
and Drug Administration has been withheld, and detractors of the transgenic salmon have
been many and vociferous (Homer, 2011; Bennett, 2011; Bennett, 2011b).
While aquaculture has come to be widely regarded as a means of bolstering
economic and social prosperity in developing and industrialized nations alike, the answer
to the difficulties associated with it is not a monolithic entity. As with most technological
advancements there are benefits and shortcomings unique to aquaculture, and every effort
must be made to ensure that the industry to moves forward in a sustainable and
responsible manner. Though researchers assert that aquaculture represents a means of
complementing captures from wild fisheries, they caution that it will almost certainly not
redeem these fisheries from their currently overexploited state (Naylor et al., 2000).
Ultimately, however, aquaculture retains tremendous potential for expansion and the
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practice of environmentally sound management. Moreover, it does much to advance the
cause of ready access to a valuable food source, which remains an indispensable
commodity now, and in the future.
Rainbow trout as a model organism
Rainbow trout have, and continue to be, of inestimable value as a model
organism; their use as such rivaled only by that of zebrafish (Danio rerio). The sheer
presence of the species within investigative research is made all the more impressive by
the breadth of the research fields in which rainbow trout have been utilized. Recent
decades have seen the use of these fish as the model organism of choice in a staggering
number of research endeavors, owing to a variety of features of the organism itself
(Thorgaard et al., 2002).
Surpassing many species, including a number of which that are closely related,
rainbow trout have distinguished themselves as a highly sought after species for research,
sport, and aquaculture purposes (Thorgaard et al., 2002). The fish remains among one of
the most widely cultivated species in aquaculture, and many of the characteristics that
have made it desirable to the aquaculture industry are the very same that have made it
equally attractive and profoundly ubiquitous as a model for research (Thorgaard et al.,
2002). The species’ importance to both aquaculture and researchers has in fact fostered a
self-sustaining reciprocity. The insight gained in the laboratory is instituted within the
industry to improve the culture of the fish, and the practices which are commonplace in
the industry, along with increasing demand for the fish, in turn serve as an impetus for
continued research into the organism.
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While zebrafish, fugu (Takifugu rubripes), and medaka (Oryzias latipes) are all
extensively used in countless areas of research, rainbow trout have rightfully commanded
the attentions and efforts of investigators. A suite of life history, anatomical, and
physiological features of rainbow trout, along with the extensive historical cultivation of
the species, have elevated these fish to the highest echelons of model organisms
(Thorgaard et al., 2002). Relative to species such as medaka and zebrafish, rainbow trout
maintain a greater body size throughout their ontogeny, which permits surgical and
physical manipulation which is impossible or excruciatingly difficult in smaller fish
(Thorgaard et al., 2002). Endocrinological investigations may be more easily realized in
a species such as rainbow trout as their body size is more amenable to canulation and
greater volumes of plasma may be obtained. Similarly, investigation into individual
tissues is a more practical reality in an organism in which ample volumes of such tissues
are available and ready access to them may be achieved (Bunton, 1996). Ablation and
replacement investigations may be accomplished not only by molecular means, but by
physical manipulation in a rainbow trout, a feat not so readily achieved in smaller
species.
The intensive energies focused on cultivating and rearing rainbow trout for
aquaculture and sport purposes have translated to a tremendous body of knowledge
regarding the maintenance and care of these fish (Thorgaard et al., 2002). Such an
extensive understanding has further encouraged their use as a model organism and made
laboratory rearing of the fish a commonplace and highly manageable practice (Thorgaard
et al., 2002). The exceptional fecundity of these fish, along with the more minimal
pecuniary demands and facility requirements necessary for maintaining large numbers of
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these fish has only served to make them more desirable as a model system (Powers et al.,
1989). Additionally, the intricacies of every stage of the life history of these fish is well
known (Powers, 1989; Thorgaard et al., 2002), facilitating not only successful
perpetuation of the fish in the laboratory, but exploitation of all phases of the
development and ontogeny of the species. Admittedly, the comparatively longer
reproduction cycles and time required to reach maturity may limit the rate with which
some investigations proceed; however, this may be counterbalanced by the advantages
afforded by the larger size of the gametes and embryos (Bailey et al., 1996; Thorgaard et
al., 2002). The production of transgenic rainbow trout has, without question, benefited
from the ease of microinjection of DNA constructs afforded by the large size of the
gametes and visual identification of the micropyle.
Considered in a macroscopic light rainbow trout prove advantageous as they are,
ultimately, a vertebrate model, albeit a more basal one. Prominent among the studies
performed in rainbow trout that have implications for human health are those concerned
with the immune system (Thorgaard et al., 2002). Many of the benefits afforded by
rainbow trout, and indeed all vertebrate models, may be found in the ease with which
they may be used as a proxy not only for vertebrate physiologies and systems, but for
human disease and pharmaceutical intervention. Rainbow trout and other fish models
have become widely used in toxicity and carcinogenicity studies for a host of reasons,
among them the inherently negligible incidence of spontaneous tumorigenesis in these
fish (Bailey et al., 1996; Law, 2003; Kissling et al., 2006; Scarpelli et al., 1963; Nunez et
al., 1991). Fish models, and rainbow trout in particular, have served as a superior
research platform for carcinogenicity studies exactly because they can readily be
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introduced to potentially carcinogenic agents by means of exposure in water, and
represent the vertebrate condition (Bailey et al., 1996, Powers, 1989). Rainbow trout
offer the opportunity to examine the impacts of carcinogenic agents throughout their
ontogeny as exposure may be introduced at any point from embryogenesis forward
(Bailey et al., 1996). Increased resolution of oncogenetic events is provided in models
such as trout as they have demonstrated a heightened sensitivity to carcinogenic and toxic
compounds (Bunton, 1996).
The minimal rates of endemic tumorigenesis in fish such as trout served to draw
immediate scrutiny when increased levels of hepatic neoplasms were found among
hatchery raised fish (Scarpelli et al., 1963; Nunez et al., 1991). Investigation into this
epidemic found aflatoxin B1 to be the causative agent, but perhaps more importantly,
demonstrated the usefulness of rainbow trout in carcinogenicity studies (Nunez et al.,
1991). Further benefit from the use of rainbow trout in such investigations is derived
from the ease with which large numbers of fish may be obtained and subjected to
treatment with compounds under investigation (Bailey et al., 1996). Investigations
utilizing such substantial numbers of study participants dramatically increases the
statistical validity of their findings (Bailey et al., 1996), and the use of nonmammalian
subjects has appeased a public which finds the use of mammalian species as research
subjects aesthetically repugnant (Law, 2003).
While rainbow trout and other fish models have historically served as viable
models for cancer research, and continue to do so presently, certain cautions are urged.
Kissling et al. (2006) note that extrapolating the findings of carcinogenicity studies in fish
to mammals should be done with important caveats, including the differential sensitivity
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of teleosts and mammals to the compounds under investigation. These researchers cite
the importance of utilizing fish models in such studies in conjunction with the use of
mammalian models, rather than in place of them, noting that the organismal milieu may
prove sufficiently disparate to preclude unqualified comparison. Similarly, the lack of
tissue homology between fish and mammals means that the findings of cancer research
performed with rainbow trout must be interpreted with full understanding of the
significant phylogenetic distance between the two, and the attendant implications (Bailey
et al., 1996; Bunton, 1996).
Among the suite of benefits afforded by the use of the rainbow trout as a model
organism is the extensive degree to which it may be used to answer inquiries into
vertebrate biology and evolution with great efficacy. The phylogenetic position occupied
by these fish represents both hindrance and help with respect to vertebrate studies. While
significant insights may be gleaned from work with these fish regarding vertebrate
physiology and biochemistry they remain a more basal vertebrate. Their ability to
approximate the mammalian conditions is somewhat constrained and they must be
considered a highly useful model, but one which cannot stand independent of others. The
evolutionary rift between these basal teleosts and mammals, and humans in particular,
conversely offers a variety of advantages as well.
The functioning of systems and physiologies in these fish provides a frame of
reference for the evolutionary development of molecules and pathways common to
vertebrate lineages. The ability to render these comparisons enables understanding of
how environment influenced evolutionary pathways, and how organ systems and
subcellular macromolecules have alternately been conserved or repurposed for events
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such as the invasion of terrestrial environments and homeothermy. Rainbow trout also
provide a means for elucidating evolutionary differences even within teleost lineages as
findings derived from their study may be compared to those of more derived species such
as fugu. The degree of conservation in the structure and function of essential signaling
molecules such as hormones may be better characterized as they are compared between
trout and murine model organisms and, ultimately, humans. The evolution of
indispensable physiologies such as those involved in ion and water balance are perhaps
nowhere better studied than in fish models such as rainbow trout, and provide a wealth of
information regarding the mechanisms involved in wholly new environments and
organismal contexts. Rainbow trout remain one of the longest standing model organisms
for a battery of amply justified reasons, and they will almost certainly remain a dominant
model as improved methodologies, widespread whole-genome sequencing, and molecular
techniques provide ever greater resolution of vertebrate biology and evolution.
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